1
|
Newton C, Pope M, Rua C, Henson R, Ji Z, Burgess N, Rodgers CT, Stangl M, Dounavi M, Castegnaro A, Koychev I, Malhotra P, Wolbers T, Ritchie K, Ritchie CW, O'Brien J, Su L, Chan D. Entorhinal-based path integration selectively predicts midlife risk of Alzheimer's disease. Alzheimers Dement 2024; 20:2779-2793. [PMID: 38421123 PMCID: PMC11032581 DOI: 10.1002/alz.13733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2023] [Revised: 01/03/2024] [Accepted: 01/17/2024] [Indexed: 03/02/2024]
Abstract
INTRODUCTION Entorhinal cortex (EC) is the first cortical region to exhibit neurodegeneration in Alzheimer's disease (AD), associated with EC grid cell dysfunction. Given the role of grid cells in path integration (PI)-based spatial behaviors, we predicted that PI impairment would represent the first behavioral change in adults at risk of AD. METHODS We compared immersive virtual reality (VR) PI ability to other cognitive domains in 100 asymptomatic midlife adults stratified by hereditary and physiological AD risk factors. In some participants, behavioral data were compared to 7T magnetic resonance imaging (MRI) measures of brain structure and function. RESULTS Midlife PI impairments predicted both hereditary and physiological AD risk, with no corresponding multi-risk impairment in episodic memory or other spatial behaviors. Impairments associated with altered functional MRI signal in the posterior-medial EC. DISCUSSION Altered PI may represent the transition point from at-risk state to disease manifestation in AD, prior to impairment in other cognitive domains.
Collapse
Affiliation(s)
- Coco Newton
- Department of PsychiatryUniversity of CambridgeCambridgeUK
| | - Marianna Pope
- Department of PsychiatryUniversity of CambridgeCambridgeUK
- Cambridgeshire and Peterborough NHS Foundation TrustCambridgeUK
| | - Catarina Rua
- Wolfson Brain Imaging CentreUniversity of CambridgeCambridgeUK
| | - Richard Henson
- Department of PsychiatryUniversity of CambridgeCambridgeUK
| | - Zilong Ji
- Institute of Cognitive NeuroscienceUCLLondonUK
| | | | | | - Matthias Stangl
- Jane and Terry Semel Institute for Neuroscience and Human BehaviorUniversity of CaliforniaLos AngelesCaliforniaUSA
- Department of Biomedical EngineeringBoston UniversityBostonMassachusettsUSA
| | | | | | - Ivan Koychev
- Department of PsychiatryWarneford HospitalOxford UniversityOxfordUK
| | | | - Thomas Wolbers
- German Centre for Neurodegenerative Diseases (DZNE)MagdeburgGermany
| | | | - Craig W. Ritchie
- Centre for Dementia PreventionWestern General HospitalUniversity of EdinburghEdinburghUK
| | - John O'Brien
- Department of PsychiatryUniversity of CambridgeCambridgeUK
- Cambridgeshire and Peterborough NHS Foundation TrustCambridgeUK
| | - Li Su
- Department of PsychiatryUniversity of CambridgeCambridgeUK
- Sheffield Institute for Translational NeuroscienceUniversity of SheffieldSheffieldUK
| | - Dennis Chan
- Department of PsychiatryUniversity of CambridgeCambridgeUK
- Institute of Cognitive NeuroscienceUCLLondonUK
| | | |
Collapse
|
2
|
Sepulveda-Falla D, Lanau CAV, White C, Serrano GE, Acosta-Uribe J, Mejía-Cupajita B, Villalba-Moreno ND, Lu P, Glatzel M, Kofler JK, Ghetti B, Frosch MP, Restrepo FL, Kosik KS, Beach TG. Comorbidities in Early-Onset Sporadic versus Presenilin-1 Mutation-Associated Alzheimer's Disease Dementia: Evidence for Dependency on Alzheimer's Disease Neuropathological Changes. MEDRXIV : THE PREPRINT SERVER FOR HEALTH SCIENCES 2023:2023.08.14.23294081. [PMID: 37646002 PMCID: PMC10462216 DOI: 10.1101/2023.08.14.23294081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/01/2023]
Abstract
Autopsy studies have demonstrated that comorbid neurodegenerative and cerebrovascular disease occur in the great majority of subjects with Alzheimer disease dementia (ADD), and are likely to additively alter the rate of decline or severity of cognitive impairment. The most important of these are Lewy body disease (LBD), TDP-43 proteinopathy and cerebrovascular disease, including white matter rarefaction (WMR) and cerebral infarcts. Comorbidities may interfere with ADD therapeutic trials evaluation of ADD clinical trials as they may not respond to AD-specific molecular therapeutics. It is possible, however, that at least some comorbidities may be, to some degree, secondary consequences of AD pathology, and if this were true then effective AD-specific therapeutics might also reduce the extent or severity of comorbid pathology. Comorbidities in ADD caused by autosomal dominant mutations such as those in the presenilin-1 (PSEN1) gene may provide an advantageous perspective on their pathogenesis, and deserve attention because these subjects are increasingly being entered into clinical trials. As ADD associated with PSEN1 mutations has a presumed single-cause etiology, and the average age at death is under 60, any comorbidities in this setting may be considered as at least partially secondary to the causative AD mechanisms rather than aging, and thus indicate whether effective ADD therapeutics may also be effective for comorbidities. In this study, we sought to compare the rates and types of ADD comorbidities between subjects with early-onset sporadic ADD (EOSADD; subjects dying under age 60) versus ADD associated with different types of PSEN1 mutations, the most common cause of early-onset autosomal dominant ADD. In particular, we were able to ascertain, for the first time, the prevalences of a fairly complete set of ADD comorbidities in United States (US) PSEN1 cases as well as the Colombian E280A PSEN1 kindred. Data for EOSADD and US PSEN1 subjects (with multiple different mutation types) was obtained from the National Alzheimer Coordinating Center (NACC). Colombian cases all had the E280A mutation and had a set of neuropathological observations classified, like the US cases according to the NACC NP10 definitions. Confirmatory of earlier reports, NACC-defined Alzheimer Disease Neuropathological Changes (ADNC) were consistently very severe in early-onset cases, whether sporadic or in PSEN1 cases, but were slightly less severe in EOSADD. Amyloid angiopathy was the only AD-associated pathology type with widely-differing severity scores between the 3 groups, with median scores of 3, 2 and 1 in the PSEN1 Colombia, PSEN1 US and EOSADD cases, respectively. Apoliprotein E genotype did not show significant proportional group differences for the possession of an E-4 or E-2 allele. Of ADD comorbidities, LBD was most common, being present in more than half of all cases in all 3 groups. For TDP-43 co-pathology, the Colombian PSEN1 group was the most affected, at about 27%, vs 16% and 11% for the US PSEN1 and sporadic US cases, respectively. Notably, hippocampal sclerosis and non-AD tau pathological conditions were not present in any of the US or Colombian PSEN1 cases, and was seen in only 3% of the EOSADD cases. Significant large-vessel atherosclerosis was present in a much larger percentage of Colombian PSEN1 cases, at almost 20% as compared to 0% and 3% of the US PSEN1 and EOSADD cases, respectively. Small-vessel disease, or arteriolosclerosis, was much more common than large vessel disease, being present in all groups between 18% and 37%. Gross and microscopic infarcts, however, as well as gross or microscopic hemorrhages, were generally absent or present at very low percentages in all groups. White matter rarefaction (WMR) was remarkably common, at almost 60%, in the US PSEN1 group, as compared to about 18% in the EOSADD cases, a significant difference. White matter rarefaction was not assessed in the Colombian PSEN1 cases. The results presented here, as well as other evidence, indicates that LBD, TDP-43 pathology and WMR, as common comorbidities with autosomal dominant and early-onset sporadic ADD, should be considered when planning clinical trials with such subjects as they may increase variability in response rates. However, they may be at least partially dependent on ADNC and thus potentially addressable by anti-amyloid or and/anti-tau therapies.
Collapse
Affiliation(s)
- Diego Sepulveda-Falla
- Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Martinistraße 52 20246 Hamburg, Gebäude Nord 27 / Raum 02.005
| | | | - Charles White
- Neuropathology Section, Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX
| | - Geidy E Serrano
- Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, 10515 W Santa Fe Drive, Sun City, AZ 85351
| | - Juliana Acosta-Uribe
- Faculty of Medicine, Neuroscience Group of Antioquia, University of Antioquia, Medellin, Colombia
- Neuroscience Research Institute and Department of Molecular Cellular and Developmental Biology, University of California Santa Barbara
| | - Barbara Mejía-Cupajita
- Faculty of Medicine, Neuroscience Group of Antioquia, University of Antioquia, Medellin, Colombia
- Neuroscience Research Institute and Department of Molecular Cellular and Developmental Biology, University of California Santa Barbara
| | - Nelson David Villalba-Moreno
- Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Martinistraße 52 20246 Hamburg, Gebäude Nord 27 / Raum 02.005
| | - Pinzhang Lu
- Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Martinistraße 52 20246 Hamburg, Gebäude Nord 27 / Raum 02.005
| | - Markus Glatzel
- Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Martinistraße 52 20246 Hamburg, Gebäude Nord 27 / Raum 02.005
| | - Julia K Kofler
- Department of Pathology, University of Pittsburgh, Pittsburgh, PA
| | - Bernardino Ghetti
- Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN
| | - Matthew P Frosch
- Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
| | | | - Kenneth S Kosik
- Neuroscience Research Institute and Department of Molecular Cellular and Developmental Biology, University of California Santa Barbara
| | - Thomas G Beach
- Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, 10515 W Santa Fe Drive, Sun City, AZ 85351
| |
Collapse
|
3
|
Bastin C, Delhaye E. Targeting the function of the transentorhinal cortex to identify early cognitive markers of Alzheimer's disease. COGNITIVE, AFFECTIVE & BEHAVIORAL NEUROSCIENCE 2023:10.3758/s13415-023-01093-5. [PMID: 37024735 DOI: 10.3758/s13415-023-01093-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 03/19/2023] [Indexed: 04/08/2023]
Abstract
Initial neuropathology of early Alzheimer's disease accumulates in the transentorhinal cortex. We review empirical data suggesting that tasks assessing cognitive functions supported by the transenthorinal cortex are impaired as early as the preclinical stages of Alzheimer's disease. These tasks span across various domains, including episodic memory, semantic memory, language, and perception. We propose that all tasks sensitive to Alzheimer-related transentorhinal neuropathology commonly rely on representations of entities supporting the processing and discrimination of items having perceptually and conceptually overlapping features. In the future, we suggest a screening tool that is sensitive and specific to very early Alzheimer's disease to probe memory and perceptual discrimination of highly similar entities.
Collapse
Affiliation(s)
- Christine Bastin
- GIGA-Cyclotron Research Centre-In Vivo Imaging, University of Liège, Allée du 6 Août, B30, 4000, Liège, Belgium.
| | - Emma Delhaye
- GIGA-Cyclotron Research Centre-In Vivo Imaging, University of Liège, Allée du 6 Août, B30, 4000, Liège, Belgium
- CICPSI, Faculdade de Psicologia, Universidade de Lisboa, Lisbon, Portugal
| |
Collapse
|
4
|
Quan M, Wang Q, Qin W, Wang W, Li F, Zhao T, Li T, Qiu Q, Cao S, Wang S, Wang Y, Jin H, Zhou A, Fang J, Jia L, Jia J. Shared and unique effects of ApoEε4 and pathogenic gene mutation on cognition and imaging in preclinical familial Alzheimer's disease. Alzheimers Res Ther 2023; 15:40. [PMID: 36850008 PMCID: PMC9972804 DOI: 10.1186/s13195-023-01192-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2022] [Accepted: 02/13/2023] [Indexed: 03/01/2023]
Abstract
BACKGROUND Neuropsychology and imaging changes have been reported in the preclinical stage of familial Alzheimer's disease (FAD). This study investigated the effects of APOEε4 and known pathogenic gene mutation on different cognitive domains and circuit imaging markers in preclinical FAD. METHODS One hundred thirty-nine asymptomatic subjects in FAD families, including 26 APOEε4 carriers, 17 APP and 20 PS1 mutation carriers, and 76 control subjects, went through a series of neuropsychological tests and MRI scanning. Test scores and imaging measures including volumes, diffusion indices, and functional connectivity (FC) of frontostriatal and hippocampus to posterior cingulate cortex pathways were compared between groups and analyzed for correlation. RESULTS Compared with controls, the APOEε4 group showed increased hippocampal volume and decreased FC of fronto-caudate pathway. The APP group showed increased recall scores in auditory verbal learning test, decreased fiber number, and increased radial diffusivity and FC of frontostriatal pathway. All three genetic groups showed decreased fractional anisotropy of hippocampus to posterior cingulate cortex pathway. These neuropsychological and imaging measures were able to discriminate genetic groups from controls, with areas under the curve from 0.733 to 0.837. Circuit imaging measures are differentially associated with scores in various cognitive scales in control and genetic groups. CONCLUSIONS There are neuropsychological and imaging changes in the preclinical stage of FAD, some of which are shared by APOEε4 and known pathogenic gene mutation, while some are unique to different genetic groups. These findings are helpful for the early identification of Alzheimer's disease and for developing generalized and individualized prevention and intervention strategies.
Collapse
Affiliation(s)
- Meina Quan
- grid.413259.80000 0004 0632 3337Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China ,National Center for Neurological Disorders and National Clinical Research Center for Geriatric Diseases, Beijing, China ,grid.24696.3f0000 0004 0369 153XClinical Center for Neurodegenerative Disease and Memory Impairment, Capital Medical University, Beijing, China ,grid.24696.3f0000 0004 0369 153XBeijing Key Laboratory of Geriatric Cognitive Disorders, Beijing, China ,grid.24696.3f0000 0004 0369 153XCenter of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China ,grid.419897.a0000 0004 0369 313XKey Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
| | - Qi Wang
- grid.413259.80000 0004 0632 3337Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China ,National Center for Neurological Disorders and National Clinical Research Center for Geriatric Diseases, Beijing, China ,grid.24696.3f0000 0004 0369 153XClinical Center for Neurodegenerative Disease and Memory Impairment, Capital Medical University, Beijing, China ,grid.24696.3f0000 0004 0369 153XBeijing Key Laboratory of Geriatric Cognitive Disorders, Beijing, China ,grid.24696.3f0000 0004 0369 153XCenter of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China ,grid.419897.a0000 0004 0369 313XKey Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
| | - Wei Qin
- grid.413259.80000 0004 0632 3337Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China ,National Center for Neurological Disorders and National Clinical Research Center for Geriatric Diseases, Beijing, China ,grid.24696.3f0000 0004 0369 153XClinical Center for Neurodegenerative Disease and Memory Impairment, Capital Medical University, Beijing, China ,grid.24696.3f0000 0004 0369 153XBeijing Key Laboratory of Geriatric Cognitive Disorders, Beijing, China ,grid.24696.3f0000 0004 0369 153XCenter of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China ,grid.419897.a0000 0004 0369 313XKey Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
| | - Wei Wang
- grid.413259.80000 0004 0632 3337Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China ,National Center for Neurological Disorders and National Clinical Research Center for Geriatric Diseases, Beijing, China ,grid.24696.3f0000 0004 0369 153XClinical Center for Neurodegenerative Disease and Memory Impairment, Capital Medical University, Beijing, China ,grid.24696.3f0000 0004 0369 153XBeijing Key Laboratory of Geriatric Cognitive Disorders, Beijing, China ,grid.24696.3f0000 0004 0369 153XCenter of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China ,grid.419897.a0000 0004 0369 313XKey Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
| | - Fangyu Li
- grid.413259.80000 0004 0632 3337Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China ,National Center for Neurological Disorders and National Clinical Research Center for Geriatric Diseases, Beijing, China ,grid.24696.3f0000 0004 0369 153XClinical Center for Neurodegenerative Disease and Memory Impairment, Capital Medical University, Beijing, China ,grid.24696.3f0000 0004 0369 153XBeijing Key Laboratory of Geriatric Cognitive Disorders, Beijing, China ,grid.24696.3f0000 0004 0369 153XCenter of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China ,grid.419897.a0000 0004 0369 313XKey Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
| | - Tan Zhao
- grid.413259.80000 0004 0632 3337Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China ,National Center for Neurological Disorders and National Clinical Research Center for Geriatric Diseases, Beijing, China
| | - Tingting Li
- grid.413259.80000 0004 0632 3337Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China ,National Center for Neurological Disorders and National Clinical Research Center for Geriatric Diseases, Beijing, China ,grid.24696.3f0000 0004 0369 153XClinical Center for Neurodegenerative Disease and Memory Impairment, Capital Medical University, Beijing, China ,grid.24696.3f0000 0004 0369 153XBeijing Key Laboratory of Geriatric Cognitive Disorders, Beijing, China ,grid.24696.3f0000 0004 0369 153XCenter of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China ,grid.419897.a0000 0004 0369 313XKey Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
| | - Qiongqiong Qiu
- grid.413259.80000 0004 0632 3337Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China ,National Center for Neurological Disorders and National Clinical Research Center for Geriatric Diseases, Beijing, China ,grid.24696.3f0000 0004 0369 153XClinical Center for Neurodegenerative Disease and Memory Impairment, Capital Medical University, Beijing, China ,grid.24696.3f0000 0004 0369 153XBeijing Key Laboratory of Geriatric Cognitive Disorders, Beijing, China ,grid.24696.3f0000 0004 0369 153XCenter of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China ,grid.419897.a0000 0004 0369 313XKey Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
| | - Shuman Cao
- grid.413259.80000 0004 0632 3337Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China ,National Center for Neurological Disorders and National Clinical Research Center for Geriatric Diseases, Beijing, China ,grid.24696.3f0000 0004 0369 153XClinical Center for Neurodegenerative Disease and Memory Impairment, Capital Medical University, Beijing, China ,grid.24696.3f0000 0004 0369 153XBeijing Key Laboratory of Geriatric Cognitive Disorders, Beijing, China ,grid.24696.3f0000 0004 0369 153XCenter of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China ,grid.419897.a0000 0004 0369 313XKey Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
| | - Shiyuan Wang
- grid.413259.80000 0004 0632 3337Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China ,National Center for Neurological Disorders and National Clinical Research Center for Geriatric Diseases, Beijing, China ,grid.24696.3f0000 0004 0369 153XClinical Center for Neurodegenerative Disease and Memory Impairment, Capital Medical University, Beijing, China ,grid.24696.3f0000 0004 0369 153XBeijing Key Laboratory of Geriatric Cognitive Disorders, Beijing, China ,grid.24696.3f0000 0004 0369 153XCenter of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China ,grid.419897.a0000 0004 0369 313XKey Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
| | - Yan Wang
- grid.413259.80000 0004 0632 3337Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China ,National Center for Neurological Disorders and National Clinical Research Center for Geriatric Diseases, Beijing, China ,grid.24696.3f0000 0004 0369 153XClinical Center for Neurodegenerative Disease and Memory Impairment, Capital Medical University, Beijing, China ,grid.24696.3f0000 0004 0369 153XBeijing Key Laboratory of Geriatric Cognitive Disorders, Beijing, China ,grid.24696.3f0000 0004 0369 153XCenter of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China ,grid.419897.a0000 0004 0369 313XKey Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
| | - Hongmei Jin
- grid.413259.80000 0004 0632 3337Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China ,National Center for Neurological Disorders and National Clinical Research Center for Geriatric Diseases, Beijing, China ,grid.24696.3f0000 0004 0369 153XClinical Center for Neurodegenerative Disease and Memory Impairment, Capital Medical University, Beijing, China ,grid.24696.3f0000 0004 0369 153XBeijing Key Laboratory of Geriatric Cognitive Disorders, Beijing, China ,grid.24696.3f0000 0004 0369 153XCenter of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China ,grid.419897.a0000 0004 0369 313XKey Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
| | - Aihong Zhou
- grid.413259.80000 0004 0632 3337Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China ,National Center for Neurological Disorders and National Clinical Research Center for Geriatric Diseases, Beijing, China ,grid.24696.3f0000 0004 0369 153XClinical Center for Neurodegenerative Disease and Memory Impairment, Capital Medical University, Beijing, China ,grid.24696.3f0000 0004 0369 153XBeijing Key Laboratory of Geriatric Cognitive Disorders, Beijing, China ,grid.24696.3f0000 0004 0369 153XCenter of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China ,grid.419897.a0000 0004 0369 313XKey Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
| | - Jiliang Fang
- grid.464297.aGuang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Longfei Jia
- grid.413259.80000 0004 0632 3337Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China ,National Center for Neurological Disorders and National Clinical Research Center for Geriatric Diseases, Beijing, China ,grid.24696.3f0000 0004 0369 153XClinical Center for Neurodegenerative Disease and Memory Impairment, Capital Medical University, Beijing, China ,grid.24696.3f0000 0004 0369 153XBeijing Key Laboratory of Geriatric Cognitive Disorders, Beijing, China ,grid.24696.3f0000 0004 0369 153XCenter of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China ,grid.419897.a0000 0004 0369 313XKey Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
| | - Jianping Jia
- Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China. .,National Center for Neurological Disorders and National Clinical Research Center for Geriatric Diseases, Beijing, China. .,Clinical Center for Neurodegenerative Disease and Memory Impairment, Capital Medical University, Beijing, China. .,Beijing Key Laboratory of Geriatric Cognitive Disorders, Beijing, China. .,Center of Alzheimer's Disease, Beijing Institute for Brain Disorders, Beijing, China. .,Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China.
| |
Collapse
|
5
|
Ringman JM, Dorrani N, Fernández SG, Signer R, Martinez-Agosto J, Lee H, Douine ED, Qiao Y, Shi Y, D’Orazio L, Pawar S, Robbie L, Kashani AH, Singer M, Byers JT, Magaki S, Guzman S, Sagare A, Zlokovic B, Cederbaum S, Nelson S, Sheikh-Bahaei N, Chui HC, Chávez-Gutiérrez L, Vinters HV. Characterization of spastic paraplegia in a family with a novel PSEN1 mutation. Brain Commun 2023; 5:fcad030. [PMID: 36895955 PMCID: PMC9991506 DOI: 10.1093/braincomms/fcad030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2021] [Revised: 09/09/2022] [Accepted: 02/13/2023] [Indexed: 02/17/2023] Open
Abstract
Spastic paraparesis has been described to occur in 13.7% of PSEN1 mutations and can be the presenting feature in 7.5%. In this paper, we describe a family with a particularly young onset of spastic paraparesis due to a novel mutation in PSEN1 (F388S). Three affected brothers underwent comprehensive imaging protocols, two underwent ophthalmological evaluations and one underwent neuropathological examination after his death at age 29. Age of onset was consistently at age 23 with spastic paraparesis, dysarthria and bradyphrenia. Pseudobulbar affect followed with progressive gait problems leading to loss of ambulation in the late 20s. Cerebrospinal fluid levels of amyloid-β, tau and phosphorylated tau and florbetaben PET were consistent with Alzheimer's disease. Flortaucipir PET showed an uptake pattern atypical for Alzheimer's disease, with disproportionate signal in posterior brain areas. Diffusion tensor imaging showed decreased mean diffusivity in widespread areas of white matter but particularly in areas underlying the peri-Rolandic cortex and in the corticospinal tracts. These changes were more severe than those found in carriers of another PSEN1 mutation, which can cause spastic paraparesis at a later age (A431E), which were in turn more severe than among persons carrying autosomal dominant Alzheimer's disease mutations not causing spastic paraparesis. Neuropathological examination confirmed the presence of cotton wool plaques previously described in association with spastic parapresis and pallor and microgliosis in the corticospinal tract with severe amyloid-β pathology in motor cortex but without unequivocal disproportionate neuronal loss or tau pathology. In vitro modelling of the effects of the mutation demonstrated increased production of longer length amyloid-β peptides relative to shorter that predicted the young age of onset. In this paper, we provide imaging and neuropathological characterization of an extreme form of spastic paraparesis occurring in association with autosomal dominant Alzheimer's disease, demonstrating robust diffusion and pathological abnormalities in white matter. That the amyloid-β profiles produced predicted the young age of onset suggests an amyloid-driven aetiology though the link between this and the white matter pathology remains undefined.
Collapse
Affiliation(s)
- John M Ringman
- Department of Neurology, Keck School of Medicine at University of Southern California, Los Angeles, CA 90033, USA
| | | | - Sara Gutiérrez Fernández
- Department of Neurosciences, VIB-KU Leuven Center for Brain & Disease Research, Leuven 3000, Belgium
- Department of Neurosciences, Leuven Brain Institute, KU Leuven, Leuven 3000, Belgium
| | - Rebecca Signer
- Department of Human Genetics, UCLA, Los Angeles, CA 90095, USA
| | | | - Hane Lee
- Department of Human Genetics, UCLA, Los Angeles, CA 90095, USA
- Department of Pathology and Laboratory Medicine, UCLA, Los Angeles, CA 90095, USA
| | - Emilie D Douine
- Department of Human Genetics, UCLA, Los Angeles, CA 90095, USA
| | - Yuchuan Qiao
- Department of Neurology, USC Stevens Neuroimaging and Informatics Institute, Los Angeles, CA 90033, USA
| | - Yonggang Shi
- Department of Neurology, USC Stevens Neuroimaging and Informatics Institute, Los Angeles, CA 90033, USA
| | - Lina D’Orazio
- Department of Neurology, Keck School of Medicine at University of Southern California, Los Angeles, CA 90033, USA
| | - Sanjay Pawar
- Department of Neurology, Keck School of Medicine at University of Southern California, Los Angeles, CA 90033, USA
| | - Leah Robbie
- Department of Neurology, Keck School of Medicine at University of Southern California, Los Angeles, CA 90033, USA
| | - Amir H Kashani
- Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD 21287, USA
| | - Maxwell Singer
- Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| | - Joshua T Byers
- Section of Neuropathology, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
| | - Shino Magaki
- Section of Neuropathology, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
| | - Sam Guzman
- Department of Pathology, Keck School of Medicine at USC, Los Angeles, CA 90033, USA
| | - Abhay Sagare
- Zilkha Neurogenetics Institute, University of Southern California, Los Angeles, CA 90033, USA
| | - Berislav Zlokovic
- Zilkha Neurogenetics Institute, University of Southern California, Los Angeles, CA 90033, USA
| | - Stephen Cederbaum
- Department of Pediatrics, UCLA, Los Angeles, CA 90095, USA
- Department of Human Genetics, UCLA, Los Angeles, CA 90095, USA
| | - Stanley Nelson
- Department of Pediatrics, UCLA, Los Angeles, CA 90095, USA
- Department of Human Genetics, UCLA, Los Angeles, CA 90095, USA
- Department of Pathology and Laboratory Medicine, UCLA, Los Angeles, CA 90095, USA
| | - Nasim Sheikh-Bahaei
- Department of Radiology, University of Southern California, Los Angeles, CA 90033, USA
| | - Helena C Chui
- Department of Neurology, Keck School of Medicine at University of Southern California, Los Angeles, CA 90033, USA
| | - Lucía Chávez-Gutiérrez
- Department of Neurosciences, VIB-KU Leuven Center for Brain & Disease Research, Leuven 3000, Belgium
- Department of Neurosciences, Leuven Brain Institute, KU Leuven, Leuven 3000, Belgium
| | - Harry V Vinters
- Section of Neuropathology, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
- Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
| |
Collapse
|
6
|
Newton C, Pope M, Rua C, Henson R, Ji Z, Burgess N, Rodgers CT, Stangl M, Dounavi ME, Castegnaro A, Koychev I, Malhotra P, Wolbers T, Ritchie K, Ritchie CW, O’Brien J, Su L, Chan D. Path integration selectively predicts midlife risk of Alzheimer's disease. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2023:2023.01.31.526473. [PMID: 36778428 PMCID: PMC9915680 DOI: 10.1101/2023.01.31.526473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The entorhinal cortex (EC) is the first cortical region to exhibit neurodegeneration in Alzheimer's disease (AD), associated with EC grid cell dysfunction. Given the role of grid cells in path integration, we predicted that path integration impairment would represent the first behavioural change in adults at-risk of AD. Using immersive virtual reality, we found that midlife path integration impairments predicted both hereditary and physiological AD risk, with no corresponding impairment on tests of episodic memory or other spatial behaviours. Impairments related to poorer angular estimation and were associated with hexadirectional grid-like fMRI signal in the posterior-medial EC. These results indicate that altered path integration may represent the transition point from at-risk state to disease onset in AD, prior to impairment in other cognitive domains.
Collapse
Affiliation(s)
- Coco Newton
- Department of Psychiatry, University of Cambridge; Cambridge, UK
| | - Marianna Pope
- Department of Psychiatry, University of Cambridge; Cambridge, UK
- Cambridgeshire and Peterborough NHS Foundation Trust; Cambridge, UK
| | - Catarina Rua
- Wolfson Brain Imaging Centre, University of Cambridge; Cambridge, UK
| | - Richard Henson
- Department of Psychiatry, University of Cambridge; Cambridge, UK
| | - Zilong Ji
- Institute of Cognitive Neuroscience, UCL; London, UK
| | - Neil Burgess
- Institute of Cognitive Neuroscience, UCL; London, UK
| | | | - Matthias Stangl
- Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California; Los Angeles, USA
| | | | | | - Ivan Koychev
- Department of Psychiatry, Oxford University; Oxford, UK
| | - Paresh Malhotra
- Department of Brain Sciences, Imperial College London; London, UK
| | - Thomas Wolbers
- German Centre for Neurodegenerative Diseases (DZNE); Magdeburg, Germany
| | - Karen Ritchie
- Inserm, Institut de Neurosciences; Montpellier, France
| | - Craig W. Ritchie
- Centre for Dementia Prevention, University of Edinburgh; Edinburgh, UK
| | - John O’Brien
- Department of Psychiatry, University of Cambridge; Cambridge, UK
- Cambridgeshire and Peterborough NHS Foundation Trust; Cambridge, UK
| | - Li Su
- Department of Psychiatry, University of Cambridge; Cambridge, UK
| | - Dennis Chan
- Institute of Cognitive Neuroscience, UCL; London, UK
| | | |
Collapse
|
7
|
Murdy TJ, Dunn AR, Singh S, Telpoukhovskaia MA, Zhang S, White JK, Kahn I, Febo M, Kaczorowski CC. Leveraging genetic diversity in mice to inform individual differences in brain microstructure and memory. Front Behav Neurosci 2023; 16:1033975. [PMID: 36703722 PMCID: PMC9871587 DOI: 10.3389/fnbeh.2022.1033975] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2022] [Accepted: 12/08/2022] [Indexed: 01/11/2023] Open
Abstract
In human Alzheimer's disease (AD) patients and AD mouse models, both differential pre-disease brain features and differential disease-associated memory decline are observed, suggesting that certain neurological features may protect against AD-related cognitive decline. The combination of these features is known as brain reserve, and understanding the genetic underpinnings of brain reserve may advance AD treatment in genetically diverse human populations. One potential source of brain reserve is brain microstructure, which is genetically influenced and can be measured with diffusion MRI (dMRI). To investigate variation of dMRI metrics in pre-disease-onset, genetically diverse AD mouse models, we utilized a population of genetically distinct AD mice produced by crossing the 5XFAD transgenic mouse model of AD to 3 inbred strains (C57BL/6J, DBA/2J, FVB/NJ) and two wild-derived strains (CAST/EiJ, WSB/EiJ). At 3 months of age, these mice underwent diffusion magnetic resonance imaging (dMRI) to probe neural microanatomy in 83 regions of interest (ROIs). At 5 months of age, these mice underwent contextual fear conditioning (CFC). Strain had a significant effect on dMRI measures in most ROIs tested, while far fewer effects of sex, sex*strain interactions, or strain*sex*5XFAD genotype interactions were observed. A main effect of 5XFAD genotype was observed in only 1 ROI, suggesting that the 5XFAD transgene does not strongly disrupt neural development or microstructure of mice in early adulthood. Strain also explained the most variance in mouse baseline motor activity and long-term fear memory. Additionally, significant effects of sex and strain*sex interaction were observed on baseline motor activity, and significant strain*sex and sex*5XFAD genotype interactions were observed on long-term memory. We are the first to study the genetic influences of brain microanatomy in genetically diverse AD mice. Thus, we demonstrated that strain is the primary factor influencing brain microstructure in young adult AD mice and that neural development and early adult microstructure are not strongly altered by the 5XFAD transgene. We also demonstrated that strain, sex, and 5XFAD genotype interact to influence memory in genetically diverse adult mice. Our results support the usefulness of the 5XFAD mouse model and convey strong relationships between natural genetic variation, brain microstructure, and memory.
Collapse
Affiliation(s)
| | - Amy R. Dunn
- The Jackson Laboratory, Bar Harbor, ME, United States
| | - Surjeet Singh
- The Jackson Laboratory, Bar Harbor, ME, United States
| | | | | | | | - Itamar Kahn
- Department of Neuroscience, Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, United States
| | - Marcelo Febo
- Department of Neuroscience, University of Florida College of Medicine, Gainesville, FL, United States
| | - Catherine C. Kaczorowski
- The Jackson Laboratory, Bar Harbor, ME, United States,*Correspondence: Catherine C. Kaczorowski,
| |
Collapse
|
8
|
Zheng Y, Li T, Xie T, Zhang Y, Liu Y, Zeng X, Wang Z, Wang L, Li H, Xie Y, Lv X, Wang J, Yu X, Wang H. Characteristics and Potential Neural Substrates of Encoding and Retrieval During Memory Binding in Amnestic Mild Cognitive Impairment. J Alzheimers Dis 2023; 94:1405-1415. [PMID: 37424465 DOI: 10.3233/jad-230154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/11/2023]
Abstract
BACKGROUND Whether encoding or retrieval failure contributes to memory binding deficit in amnestic mild cognitive impairment (aMCI) has not been elucidated. Also, the potential brain structural substrates of memory binding remained undiscovered. OBJECTIVE To investigate the characteristics and brain atrophy pattern of encoding and retrieval performance during memory binding in aMCI. METHODS Forty-three individuals with aMCI and 37 cognitively normal controls were recruited. The Memory Binding Test (MBT) was used to measure memory binding performance. The immediate and delayed memory binding indices were computed by using the free and cued paired recall scores. Partial correlation analysis was performed to map the relationship between regional gray matter volume and memory binding performance. RESULTS The memory binding performance in the learning and retrieval phases was worse in the aMCI group than in the control group (F = 22.33 to 52.16, all p < 0.001). The immediate and delayed memory binding index in the aMCI group was lower than that in the control group (p < 0.05). The gray matter volume of the left inferior temporal gyrus was positively correlated with memory binding test scores (r = 0.49 to 0.61, p < 0.05) as well as the immediate (r = 0.39, p < 0.05) and delayed memory binding index (r = 0.42, p < 0.05) in the aMCI group. CONCLUSION aMCI may be primarily characterized by a deficit in encoding phase during the controlled learning process. Volumetric losses in the left inferior temporal gyrus may contribute to encoding failure.
Collapse
Affiliation(s)
- Yaonan Zheng
- Dementia Care and Research Center, Peking University Institute of Mental Health (Sixth Hospital), Beijing, China
- National Clinical Research Center for Mental Disorders (Peking University), NHC Key Laboratory for Mental Health, Beijing, China
| | - Tao Li
- Dementia Care and Research Center, Peking University Institute of Mental Health (Sixth Hospital), Beijing, China
- National Clinical Research Center for Mental Disorders (Peking University), NHC Key Laboratory for Mental Health, Beijing, China
| | - Teng Xie
- Dementia Care and Research Center, Peking University Institute of Mental Health (Sixth Hospital), Beijing, China
- National Clinical Research Center for Mental Disorders (Peking University), NHC Key Laboratory for Mental Health, Beijing, China
| | - Ying Zhang
- Dementia Care and Research Center, Peking University Institute of Mental Health (Sixth Hospital), Beijing, China
- National Clinical Research Center for Mental Disorders (Peking University), NHC Key Laboratory for Mental Health, Beijing, China
- Beijing Anding Hospital, Capital Medical University, Beijing, China
| | - Ying Liu
- Department of Radiology, Peking University Third Hospital, Beijing, China
| | - Xiangzhu Zeng
- Department of Radiology, Peking University Third Hospital, Beijing, China
| | - Zhijiang Wang
- Dementia Care and Research Center, Peking University Institute of Mental Health (Sixth Hospital), Beijing, China
- National Clinical Research Center for Mental Disorders (Peking University), NHC Key Laboratory for Mental Health, Beijing, China
| | - Luchun Wang
- Dementia Care and Research Center, Peking University Institute of Mental Health (Sixth Hospital), Beijing, China
- National Clinical Research Center for Mental Disorders (Peking University), NHC Key Laboratory for Mental Health, Beijing, China
| | - Huizi Li
- Dementia Care and Research Center, Peking University Institute of Mental Health (Sixth Hospital), Beijing, China
- National Clinical Research Center for Mental Disorders (Peking University), NHC Key Laboratory for Mental Health, Beijing, China
| | - Yuhan Xie
- Dementia Care and Research Center, Peking University Institute of Mental Health (Sixth Hospital), Beijing, China
- National Clinical Research Center for Mental Disorders (Peking University), NHC Key Laboratory for Mental Health, Beijing, China
| | - Xiaozhen Lv
- Dementia Care and Research Center, Peking University Institute of Mental Health (Sixth Hospital), Beijing, China
- National Clinical Research Center for Mental Disorders (Peking University), NHC Key Laboratory for Mental Health, Beijing, China
| | - Jing Wang
- Dementia Care and Research Center, Peking University Institute of Mental Health (Sixth Hospital), Beijing, China
- National Clinical Research Center for Mental Disorders (Peking University), NHC Key Laboratory for Mental Health, Beijing, China
| | - Xin Yu
- Dementia Care and Research Center, Peking University Institute of Mental Health (Sixth Hospital), Beijing, China
- National Clinical Research Center for Mental Disorders (Peking University), NHC Key Laboratory for Mental Health, Beijing, China
| | - Huali Wang
- Dementia Care and Research Center, Peking University Institute of Mental Health (Sixth Hospital), Beijing, China
- National Clinical Research Center for Mental Disorders (Peking University), NHC Key Laboratory for Mental Health, Beijing, China
| |
Collapse
|
9
|
Pathological Slow-Wave Activity and Impaired Working Memory Binding in Post-Traumatic Amnesia. J Neurosci 2022; 42:9193-9210. [PMID: 36316155 PMCID: PMC9761692 DOI: 10.1523/jneurosci.0564-22.2022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2022] [Revised: 10/02/2022] [Accepted: 10/04/2022] [Indexed: 11/06/2022] Open
Abstract
Associative binding is key to normal memory function and is transiently disrupted during periods of post-traumatic amnesia (PTA) following traumatic brain injury (TBI). Electrophysiological abnormalities, including low-frequency activity, are common following TBI. Here, we investigate associative memory binding during PTA and test the hypothesis that misbinding is caused by pathological slowing of brain activity disrupting cortical communication. Thirty acute moderate to severe TBI patients (25 males; 5 females) and 26 healthy controls (20 males; 6 females) were tested with a precision working memory paradigm requiring the association of object and location information. Electrophysiological effects of TBI were assessed using resting-state EEG in a subsample of 17 patients and 21 controls. PTA patients showed abnormalities in working memory function and made significantly more misbinding errors than patients who were not in PTA and controls. The distribution of localization responses was abnormally biased by the locations of nontarget items for patients in PTA, suggesting a specific impairment of object and location binding. Slow-wave activity was increased following TBI. Increases in the δ-α ratio indicative of an increase in low-frequency power specifically correlated with binding impairment in working memory. Connectivity changes in TBI did not correlate with binding impairment. Working memory and electrophysiological abnormalities normalized at 6 month follow-up. These results show that patients in PTA show high rates of misbinding that are associated with a pathological shift toward lower-frequency oscillations.SIGNIFICANCE STATEMENT How do we remember what was where? The mechanism by which information (e.g., object and location) is integrated in working memory is a central question for cognitive neuroscience. Following significant head injury, many patients will experience a period of post-traumatic amnesia (PTA) during which this associative binding is disrupted. This may be because of electrophysiological changes in the brain. Using a precision working memory test and resting-state EEG, we show that PTA patients demonstrate impaired binding ability, and this is associated with a shift toward slower-frequency activity on EEG. Abnormal EEG connectivity was observed but was not specific to PTA or binding ability. These findings contribute to both our mechanistic understanding of working memory binding and PTA pathophysiology.
Collapse
|
10
|
Yu M, Sporns O, Saykin AJ. The human connectome in Alzheimer disease - relationship to biomarkers and genetics. Nat Rev Neurol 2021; 17:545-563. [PMID: 34285392 PMCID: PMC8403643 DOI: 10.1038/s41582-021-00529-1] [Citation(s) in RCA: 87] [Impact Index Per Article: 29.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/10/2021] [Indexed: 02/06/2023]
Abstract
The pathology of Alzheimer disease (AD) damages structural and functional brain networks, resulting in cognitive impairment. The results of recent connectomics studies have now linked changes in structural and functional network organization in AD to the patterns of amyloid-β and tau accumulation and spread, providing insights into the neurobiological mechanisms of the disease. In addition, the detection of gene-related connectome changes might aid in the early diagnosis of AD and facilitate the development of personalized therapeutic strategies that are effective at earlier stages of the disease spectrum. In this article, we review studies of the associations between connectome changes and amyloid-β and tau pathologies as well as molecular genetics in different subtypes and stages of AD. We also highlight the utility of connectome-derived computational models for replicating empirical findings and for tracking and predicting the progression of biomarker-indicated AD pathophysiology.
Collapse
Affiliation(s)
- Meichen Yu
- Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, IN, USA
- Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA
- Indiana University Network Science Institute, Bloomington, IN, USA
| | - Olaf Sporns
- Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, IN, USA
- Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA
- Indiana University Network Science Institute, Bloomington, IN, USA
- Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA
| | - Andrew J Saykin
- Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, IN, USA.
- Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA.
- Indiana University Network Science Institute, Bloomington, IN, USA.
| |
Collapse
|
11
|
Ibanez A, Parra MA, Butler C. The Latin America and the Caribbean Consortium on Dementia (LAC-CD): From Networking to Research to Implementation Science. J Alzheimers Dis 2021; 82:S379-S394. [PMID: 33492297 PMCID: PMC8293660 DOI: 10.3233/jad-201384] [Citation(s) in RCA: 32] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
In comparison with other regions, dementia prevalence in Latin America is growing rapidly, along with the consequent clinical, social, and economic burden upon patients and their families. The combination of fragile health care systems, large social inequalities, and isolated clinical and research initiatives makes the coordination of efforts imperative. The Latin America and the Caribbean Consortium on Dementia (LAC-CD) is a regional organization overseeing and promoting clinical and research activities on dementia. Here, we first provide an overview of the consortium, highlighting the antecedents and current mission. Then, we present the consortium’s regional research, including the multi-partner consortium to expand dementia research in Latin America (ReDLat), which aims to identify the unique genetic, social, and economic factors that drive Alzheimer’s and frontotemporal dementia presentation in LAC relative to the US. We describe an extension of ReDLat which aims to develop affordable markers of disease subtype and severity using high density EEG. We introduce current initiatives promoting regional diagnosis, visibility, and capacity, including the forthcoming launch of the Latin American Brain Health Institute (BrainLat). We discuss LAC-CD-led advances in brain health diplomacy, including an assessment of responses to the impact of COVID-19 on people with dementia and examining the knowledge of public policies among experts in the region. Finally, we present the current knowledge-to-action framework, which paves the way for a future regional action plan. Coordinated actions are crucial to forging strong regional bonds, supporting the implementation of regional dementia plans, improving health systems, and expanding research collaborations across Latin America.
Collapse
Affiliation(s)
- Agustin Ibanez
- Global Brain Health Institute (GBHI), University of California San Francisco (UCSF), San Francisco, CA, USA.,Cognitive Neuroscience Center (CNC), Universidad de San Andrés, Buenos Aires, Argentina.,National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.,Universidad Autónoma del Caribe, Barranquilla, Barranquilla, Colombia.,Latin American Institute for Brain Health (BrainLat), Center for Social and Cognitive Neuroscience (CSCN), Universidad Adolfo Ibanez, Santiago de Chile, Chile
| | - Mario A Parra
- Universidad Autónoma del Caribe, Barranquilla, Barranquilla, Colombia.,School of Psychological Sciences and Health, University of Strathclyde, Glasgow, UK
| | - Christopher Butler
- Department of Brain Sciences, Imperial College London, UK.,Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.,Instituto de Neurología Cognitiva, Buenos Aires, Argentina.,Departamento de Neurología, Pontificia Universidad de Chile, Santiago, Chile
| | | |
Collapse
|
12
|
Shenzhiling oral solution promotes myelin repair through PI3K/Akt-mTOR pathway in STZ-induced SAD mice. 3 Biotech 2021; 11:361. [PMID: 34295606 DOI: 10.1007/s13205-021-02900-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2021] [Accepted: 06/16/2021] [Indexed: 12/22/2022] Open
Abstract
Most forms of Alzheimer's disease are sporadic. A model of sporadic Alzheimer's disease induced with bilateral intraventricular injection of streptozotocin leads to insulin resistance in the brain accompanied by memory decline, synaptic dysfunction, amyloid plaque deposition, oxidative stress, and neuronal apoptosis, all of which mimic the pathologies associated with sporadic Alzheimer's disease. Myelin injury is an essential component of Alzheimer's disease, playing a key role in early cognitive impairment. Our previously research found that sporadic Alzheimer's disease model showed myelin injury and that Shenzheling oral solution improved mild-to-moderate Alzheimer's disease; therefore, the protective effect of Shenzheling oral solution on myelin injury in early cognitive impairment is worth attention. In this study, the Morris water maze test results showed impairments in the learning and memory functions of mice in the model group, whereas the learning and memory function significantly improved after drug intervention. Immunohistochemistry showed increased β-amyloid plaques in the model group and decreased amounts in the drug group. Moreover, results of electron microscopy, western blot, and polymerase chain reaction showed that Shenzhiling oral solution improved early cognitive impairment and repaired myelin sheath damage; the potential mechanism of these effects may relate to the PI3K/Akt-mTOR signaling pathway. These findings support the application and promotion of Shenzhiling oral solution to treat sporadic Alzheimer's disease. SUPPLEMENTARY INFORMATION The online version contains supplementary material available at 10.1007/s13205-021-02900-x.
Collapse
|
13
|
Cecchini MA, Yassuda MS, Squarzoni P, Coutinho AM, de Paula Faria D, Duran FLDS, Costa NAD, Porto FHDG, Nitrini R, Forlenza OV, Brucki SMD, Buchpiguel CA, Parra MA, Busatto GF. Deficits in short-term memory binding are detectable in individuals with brain amyloid deposition in the absence of overt neurodegeneration in the Alzheimer's disease continuum. Brain Cogn 2021; 152:105749. [PMID: 34022637 DOI: 10.1016/j.bandc.2021.105749] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2021] [Revised: 04/24/2021] [Accepted: 05/03/2021] [Indexed: 10/21/2022]
Abstract
The short-term memory binding (STMB) test involves the ability to hold in memory the integration between surface features, such as shapes and colours. The STMB test has been used to detect Alzheimer's disease (AD) at different stages, from preclinical to dementia, showing promising results. The objective of the present study was to verify whether the STMB test could differentiate patients with distinct biomarker profiles in the AD continuum. The sample comprised 18 cognitively unimpaired (CU) participants, 30 mild cognitive impairment (MCI) and 23 AD patients. All participants underwent positron emission tomography (PET) with Pittsburgh compound-B labelled with carbon-11 ([11C]PIB) assessing amyloid beta (Aβ) aggregation (A) and 18fluorine-fluorodeoxyglucose ([18F]FDG)-PET assessing neurodegeneration (N) (A-N- [n = 35]); A+N- [n = 11]; A+ N+ [n = 19]). Participants who were negative and positive for amyloid deposition were compared in the absence (A-N- vs. A+N-) of neurodegeneration. When compared with the RAVLT and SKT memory tests, the STMB was the only cognitive task that differentiated these groups, predicting the group outcome in logistic regression analyses. The STMB test showed to be sensitive to the signs of AD pathology and may represent a cognitive marker within the AD continuum.
Collapse
Affiliation(s)
- Mario Amore Cecchini
- Human Cognitive Neuroscience, Psychology, University of Edinburgh, Edinburgh, United Kingdom
| | - Mônica Sanches Yassuda
- Neurology, School of Medicine, University of São Paulo, São Paulo, Brazil; Gerontology, School of Arts, Sciences and Humanities, University of São Paulo, São Paulo, Brazil.
| | - Paula Squarzoni
- Laboratory of Psychiatric Neuroimaging (LIM-21), Departamento e Instituto de Psiquiatria, Hospital das Clínicas, School of Medicine, University of São Paulo, São Paulo, Brazil
| | - Artur Martins Coutinho
- Laboratory of Psychiatric Neuroimaging (LIM-21), Departamento e Instituto de Psiquiatria, Hospital das Clínicas, School of Medicine, University of São Paulo, São Paulo, Brazil; Laboratory of Nuclear Medicine (LIM43), Centro de Medicina Nuclear, Department of Radiology and Oncology, School of Medicine, University of São Paulo, São Paulo, Brazil
| | - Daniele de Paula Faria
- Laboratory of Neuroscience (LIM 27), Department of Psychiatry, School of Medicine, University of São Paulo, São Paulo, Brazil; Núcleo de Apoio a Pesquisa em Neurociência Aplicada (NAPNA), University of São Paulo, São Paulo, Brazil
| | - Fábio Luiz de Souza Duran
- Laboratory of Psychiatric Neuroimaging (LIM-21), Departamento e Instituto de Psiquiatria, Hospital das Clínicas, School of Medicine, University of São Paulo, São Paulo, Brazil
| | - Naomi Antunes da Costa
- Laboratory of Psychiatric Neuroimaging (LIM-21), Departamento e Instituto de Psiquiatria, Hospital das Clínicas, School of Medicine, University of São Paulo, São Paulo, Brazil
| | - Fábio Henrique de Gobbi Porto
- Laboratory of Psychiatric Neuroimaging (LIM-21), Departamento e Instituto de Psiquiatria, Hospital das Clínicas, School of Medicine, University of São Paulo, São Paulo, Brazil
| | - Ricardo Nitrini
- Neurology, School of Medicine, University of São Paulo, São Paulo, Brazil
| | - Orestes Vicente Forlenza
- Laboratory of Neuroscience (LIM 27), Department of Psychiatry, School of Medicine, University of São Paulo, São Paulo, Brazil
| | | | - Carlos Alberto Buchpiguel
- Laboratory of Nuclear Medicine (LIM43), Centro de Medicina Nuclear, Department of Radiology and Oncology, School of Medicine, University of São Paulo, São Paulo, Brazil
| | - Mario A Parra
- School of Psychological Sciences and Health, University of Strathclyde, Glasgow, United Kingdom
| | - Geraldo F Busatto
- Laboratory of Psychiatric Neuroimaging (LIM-21), Departamento e Instituto de Psiquiatria, Hospital das Clínicas, School of Medicine, University of São Paulo, São Paulo, Brazil; Núcleo de Apoio a Pesquisa em Neurociência Aplicada (NAPNA), University of São Paulo, São Paulo, Brazil
| |
Collapse
|
14
|
Gellersen HM, Coughlan G, Hornberger M, Simons JS. Memory precision of object-location binding is unimpaired in APOE ε4-carriers with spatial navigation deficits. Brain Commun 2021; 3:fcab087. [PMID: 33987536 PMCID: PMC8108563 DOI: 10.1093/braincomms/fcab087] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2020] [Revised: 03/09/2021] [Accepted: 03/29/2021] [Indexed: 12/19/2022] Open
Abstract
Research suggests that tests of memory fidelity, feature binding and spatial navigation are promising for early detection of subtle behavioural changes related to Alzheimer's disease. In the absence of longitudinal data, one way of testing the early detection potential of cognitive tasks is through the comparison of individuals at different genetic risk for Alzheimer's dementia. Most studies have done so using samples aged 70 years or older. Here, we tested whether memory fidelity of long-term object-location binding may be a sensitive marker even among cognitively healthy individuals in their mid-60s by comparing participants at low and higher risk based on presence of the ε4-allele of the apolipoprotein gene (n = 26 ε3ε3, n = 20 ε3ε4 carriers). We used a continuous report paradigm in a visual memory task that required participants to recreate the spatial position of objects in a scene. We employed mixture modelling to estimate the two distinct memory processes that underpin the trial-by-trial variation in localization errors: retrieval success which indexes the proportion of trials where participants recalled any information about an object's position and the precision with which participants retrieved this information. Prior work has shown that these memory paradigms that separate retrieval success from precision are capable of detecting subtle differences in mnemonic fidelity even when retrieval success could not. Nonetheless, Bayesian analyses found good evidence that ε3ε4 carriers did not remember fewer object locations [F(1, 42) = 0.450, P = 0.506, BF01 = 3.02], nor was their precision for the spatial position of objects reduced compared to ε3ε3 carriers [F(1, 42) = 0.12, P = 0.726, BF01 = 3.19]. Because the participants in the sample presented here were a subset of a study on apolipoprotein ε4-carrier status and spatial navigation in the Sea Hero Quest game [Coughlan et al., 2019. PNAS, 116(9)], we obtained these data to contrast genetic effects on the two tasks within the same sample (n = 33). Despite the smaller sample size, wayfinding deficits among ε3ε4 carriers could be replicated [F(1, 33) = 5.60, P = 0.024, BF10 = 3.44]. Object-location memory metrics and spatial navigation scores were not correlated (all r < 0.25, P > 0.1, 0 < BF10 < 3). These findings show spared object-location binding in the presence of a detrimental apolipoprotein ε4 effect on spatial navigation. This suggests that the sensitivity of memory fidelity and binding tasks may not extend to individuals with one ε4-allele in their early to mid-60s. The results provide further support to prior proposals that spatial navigation may be a sensitive marker for the earliest cognitive changes in Alzheimer's disease, even before episodic memory.
Collapse
Affiliation(s)
- Helena M Gellersen
- Department of Psychology, University of Cambridge, Cambridge CB2 3EB, UK
| | - Gillian Coughlan
- Rotman Research Institute, Baycrest Hospital, Toronto, ON M6A 1W1, Canada
| | | | - Jon S Simons
- Department of Psychology, University of Cambridge, Cambridge CB2 3EB, UK
| |
Collapse
|
15
|
Manga A, Madurka P, Vakli P, Kirwan CB, Vidnyánszky Z. Investigation of the relationship between visual feature binding in short- and long-term memory in healthy aging. Learn Mem 2021; 28:109-113. [PMID: 33723030 PMCID: PMC7970738 DOI: 10.1101/lm.052548.120] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2020] [Accepted: 01/16/2021] [Indexed: 11/24/2022]
Abstract
Binding visual features into coherent object representations is essential both in short- and long-term memory. However, the relationship between feature binding processes at different memory delays remains unexplored. Here, we addressed this question by using the Mnemonic Similarity Task and a delayed-estimation working memory task on a large sample of older adults. The results revealed that higher propensity to misbind object features in working memory is associated with lower lure discrimination performance in the mnemonic similarity task, suggesting that shared feature binding processes underlie the formation of coherent short- and long-term visual object memory representations.
Collapse
Affiliation(s)
- Annamária Manga
- Brain Imaging Centre, Research Centre for Natural Sciences, Budapest 1117, Hungary
- Department of Cognitive Science, Budapest University of Technology and Economics, Budapest 1111, Hungary
| | - Petra Madurka
- Brain Imaging Centre, Research Centre for Natural Sciences, Budapest 1117, Hungary
| | - Pál Vakli
- Brain Imaging Centre, Research Centre for Natural Sciences, Budapest 1117, Hungary
| | - C Brock Kirwan
- Department of Psychology and Neuroscience Center, Brigham Young University, Provo, Utah 84602, USA
| | - Zoltán Vidnyánszky
- Brain Imaging Centre, Research Centre for Natural Sciences, Budapest 1117, Hungary
| |
Collapse
|
16
|
Ibanez A, Yokoyama JS, Possin KL, Matallana D, Lopera F, Nitrini R, Takada LT, Custodio N, Sosa Ortiz AL, Avila-Funes JA, Behrens MI, Slachevsky A, Myers RM, Cochran JN, Brusco LI, Bruno MA, Brucki SMD, Pina-Escudero SD, Okada de Oliveira M, Donnelly Kehoe P, Garcia AM, Cardona JF, Santamaria-Garcia H, Moguilner S, Duran-Aniotz C, Tagliazucchi E, Maito M, Longoria Ibarrola EM, Pintado-Caipa M, Godoy ME, Bakman V, Javandel S, Kosik KS, Valcour V, Miller BL. The Multi-Partner Consortium to Expand Dementia Research in Latin America (ReDLat): Driving Multicentric Research and Implementation Science. Front Neurol 2021; 12:631722. [PMID: 33776890 PMCID: PMC7992978 DOI: 10.3389/fneur.2021.631722] [Citation(s) in RCA: 47] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2020] [Accepted: 02/15/2021] [Indexed: 12/17/2022] Open
Abstract
Dementia is becoming increasingly prevalent in Latin America, contrasting with stable or declining rates in North America and Europe. This scenario places unprecedented clinical, social, and economic burden upon patients, families, and health systems. The challenges prove particularly pressing for conditions with highly specific diagnostic and management demands, such as frontotemporal dementia. Here we introduce a research and networking initiative designed to tackle these ensuing hurdles, the Multi-partner consortium to expand dementia research in Latin America (ReDLat). First, we present ReDLat's regional research framework, aimed at identifying the unique genetic, social, and economic factors driving the presentation of frontotemporal dementia and Alzheimer's disease in Latin America relative to the US. We describe ongoing ReDLat studies in various fields and ongoing research extensions. Then, we introduce actions coordinated by ReDLat and the Latin America and Caribbean Consortium on Dementia (LAC-CD) to develop culturally appropriate diagnostic tools, regional visibility and capacity building, diplomatic coordination in local priority areas, and a knowledge-to-action framework toward a regional action plan. Together, these research and networking initiatives will help to establish strong cross-national bonds, support the implementation of regional dementia plans, enhance health systems' infrastructure, and increase translational research collaborations across the continent.
Collapse
Affiliation(s)
- Agustin Ibanez
- The Global Brain Health Institute (GBHI), University of California, San Francisco, San Francisco, CA, United States
- The Global Brain Health Institute (GBHI), Trinity College Dublin, Dublin, Ireland
- Cognitive Neuroscience Center, Universidad de San Andrés, Buenos Aires, Argentina
- National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina
- School of Psychology, Center for Social and Cognitive Neuroscience, Latin American Institute for Brain Health (BrainLat), Universidad Adolfo Ibanez, Adolfo Ibanez University, Santiago, Chile
| | - Jennifer S. Yokoyama
- The Global Brain Health Institute (GBHI), University of California, San Francisco, San Francisco, CA, United States
- The Global Brain Health Institute (GBHI), Trinity College Dublin, Dublin, Ireland
- Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, United States
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, United States
| | - Katherine L. Possin
- The Global Brain Health Institute (GBHI), University of California, San Francisco, San Francisco, CA, United States
- The Global Brain Health Institute (GBHI), Trinity College Dublin, Dublin, Ireland
- Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, United States
| | - Diana Matallana
- Psychiatry Department, School of Medicine, Aging Institute, Pontificia Universidad Javeriana, Bogotá, Colombia
- Memory and Cognition Clinic, Intellectus, Hospital Universitario San Ignacio, Bogotá, Colombia
- Mental Health Unit, Hospital Universitario Santa Fe de Bogotá, Bogotá, Colombia
| | - Francisco Lopera
- Grupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellín, Colombia
| | - Ricardo Nitrini
- Cognitive and Behavioral Neurology Unit, Hospital das Clinicas, University of São Paulo Medical School, São Paulo, Brazil
| | - Leonel T. Takada
- Cognitive and Behavioral Neurology Unit, Hospital das Clinicas, University of São Paulo Medical School, São Paulo, Brazil
| | - Nilton Custodio
- Unit Cognitive Impairment and Dementia Prevention, Cognitive Neurology Center, Peruvian Institute of Neurosciences, Lima, Perú
| | - Ana Luisa Sosa Ortiz
- Instituto Nacional de Neurologia y Neurocirugia MVS, Universidad Nacional Autonoma de Mexico, Mexico, Mexico
| | - José Alberto Avila-Funes
- Department of Geriatrics, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico
- Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Bordeaux, France
| | - Maria Isabel Behrens
- Centro de Investigación Clínica Avanzada, Hospital Clínico, Facultad de Medicina Universidad de Chile, Santiago, Chile
- Departamento de Neurología y Neurocirugía, Hospital Clínico Universidad de Chile, Santiago, Chile
- Departamento de Neurociencia, Facultad de Medicina Universidad de Chile, Santiago, Chile
- Clínica Alemana Santiago, Universidad del Desarrollo, Santiago, Chile
| | - Andrea Slachevsky
- Clínica Alemana Santiago, Universidad del Desarrollo, Santiago, Chile
- Geroscience Center for Brain Health and Metabolism (GERO), Santiago, Chile
- Neuropsychology and Clinical Neuroscience Laboratory, Physiopathology Department, Institute of Biomedical Sciences, Neuroscience and East Neuroscience, Santiago, Chile
- Faculty of Medicine, University of Chile, Santiago, Chile
- Memory and Neuropsychiatric Clinic (CMYN) Neurology Department, Faculty of Medicine, Hospital del Salvador, University of Chile, Santiago, Chile
| | - Richard M. Myers
- Hudson Alpha Institute for Biotechnology, Huntsville, AL, United States
| | | | - Luis Ignacio Brusco
- Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
- ALZAR – Alzheimer, Buenos Aires, Argentina
| | - Martin A. Bruno
- National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina
- Facultad Ciencias Médicas, Instituto Ciencias Biomédicas, Universidad Católica de Cuyo, San Juan, Argentina
| | - Sonia M. D. Brucki
- Cognitive and Behavioral Neurology Unit, Hospital das Clinicas, University of São Paulo Medical School, São Paulo, Brazil
- Hospital Santa Marcelina, São Paulo, São Paulo, Brazil
| | - Stefanie Danielle Pina-Escudero
- The Global Brain Health Institute (GBHI), University of California, San Francisco, San Francisco, CA, United States
- The Global Brain Health Institute (GBHI), Trinity College Dublin, Dublin, Ireland
- Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, United States
| | - Maira Okada de Oliveira
- The Global Brain Health Institute (GBHI), University of California, San Francisco, San Francisco, CA, United States
- The Global Brain Health Institute (GBHI), Trinity College Dublin, Dublin, Ireland
- Cognitive and Behavioral Neurology Unit, Hospital das Clinicas, University of São Paulo Medical School, São Paulo, Brazil
- Hospital Santa Marcelina, São Paulo, São Paulo, Brazil
| | - Patricio Donnelly Kehoe
- National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina
- Multimedia Signal Processing Group - Neuroimage Division, French-Argentine International Center for Information and Systems Sciences, Rosario, Argentina
| | - Adolfo M. Garcia
- The Global Brain Health Institute (GBHI), University of California, San Francisco, San Francisco, CA, United States
- The Global Brain Health Institute (GBHI), Trinity College Dublin, Dublin, Ireland
- Cognitive Neuroscience Center, Universidad de San Andrés, Buenos Aires, Argentina
- National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina
- Faculty of Education, National University of Cuyo, Mendoza, Argentina
| | | | - Hernando Santamaria-Garcia
- Memory and Cognition Clinic, Intellectus, Hospital Universitario San Ignacio, Bogotá, Colombia
- Ph.D. Program in Neuroscience, Department of Psychiatry, Physiology, Pontificia Universidad Javeriana, Bogotá, Colombia
| | - Sebastian Moguilner
- The Global Brain Health Institute (GBHI), University of California, San Francisco, San Francisco, CA, United States
- The Global Brain Health Institute (GBHI), Trinity College Dublin, Dublin, Ireland
| | - Claudia Duran-Aniotz
- School of Psychology, Center for Social and Cognitive Neuroscience, Latin American Institute for Brain Health (BrainLat), Universidad Adolfo Ibanez, Adolfo Ibanez University, Santiago, Chile
| | - Enzo Tagliazucchi
- Departamento de Física, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Marcelo Maito
- Cognitive Neuroscience Center, Universidad de San Andrés, Buenos Aires, Argentina
| | | | - Maritza Pintado-Caipa
- The Global Brain Health Institute (GBHI), University of California, San Francisco, San Francisco, CA, United States
- The Global Brain Health Institute (GBHI), Trinity College Dublin, Dublin, Ireland
- Unit Cognitive Impairment and Dementia Prevention, Cognitive Neurology Center, Peruvian Institute of Neurosciences, Lima, Perú
| | - Maria Eugenia Godoy
- Cognitive Neuroscience Center, Universidad de San Andrés, Buenos Aires, Argentina
| | - Vera Bakman
- The Global Brain Health Institute (GBHI), University of California, San Francisco, San Francisco, CA, United States
- The Global Brain Health Institute (GBHI), Trinity College Dublin, Dublin, Ireland
| | - Shireen Javandel
- Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, United States
| | - Kenneth S. Kosik
- Department of Molecular, Cellular, and Developmental Biology, Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, CA, United States
| | - Victor Valcour
- The Global Brain Health Institute (GBHI), University of California, San Francisco, San Francisco, CA, United States
- The Global Brain Health Institute (GBHI), Trinity College Dublin, Dublin, Ireland
- Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, United States
| | - Bruce L. Miller
- The Global Brain Health Institute (GBHI), University of California, San Francisco, San Francisco, CA, United States
- The Global Brain Health Institute (GBHI), Trinity College Dublin, Dublin, Ireland
- Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, United States
| |
Collapse
|
17
|
Parra MA, Baez S, Sedeño L, Gonzalez Campo C, Santamaría‐García H, Aprahamian I, Bertolucci PHF, Bustin J, Camargos Bicalho MA, Cano‐Gutierrez C, Caramelli P, Chaves MLF, Cogram P, Beber BC, Court FA, de Souza LC, Custodio N, Damian A, de la Cruz M, Diehl Rodriguez R, Brucki SMD, Fajersztajn L, Farías GA, De Felice FG, Ferrari R, de Oliveira FF, Ferreira ST, Ferretti C, Figueredo Balthazar ML, Ferreira Frota NA, Fuentes P, García AM, Garcia PJ, de Gobbi Porto FH, Duque Peñailillo L, Engler HW, Maier I, Mata IF, Gonzalez‐Billault C, Lopez OL, Morelli L, Nitrini R, Quiroz YT, Guerrero Barragan A, Huepe D, Pio FJ, Suemoto CK, Kochhann R, Kochen S, Kumfor F, Lanata S, Miller B, Mansur LL, Hosogi ML, Lillo P, Llibre Guerra J, Lira D, Lopera F, Comas A, Avila‐Funes JA, Sosa AL, Ramos C, Resende EDPF, Snyder HM, Tarnanas I, Yokoyama J, Llibre J, Cardona JF, Possin K, Kosik KS, Montesinos R, Moguilner S, Solis PCL, Ferretti‐Rebustini REDL, Ramirez JM, Matallana D, Mbakile‐Mahlanza L, Marques Ton AM, Tavares RM, Miotto EC, Muniz‐Terrera G, Muñoz‐Nevárez LA, Orozco D, Okada de Oliveira M, Piguet O, Pintado Caipa M, Piña Escudero SD, Schilling LP, Rodrigues Palmeira AL, Yassuda MS, Santacruz‐Escudero JM, Serafim RB, Smid J, Slachevsky A, Serrano C, Soto‐Añari M, Takada LT, Grinberg LT, Teixeira AL, Barbosa MT, Trépel D, Ibanez A. Dementia in Latin America: Paving the way toward a regional action plan. Alzheimers Dement 2021; 17:295-313. [PMID: 33634602 PMCID: PMC7984223 DOI: 10.1002/alz.12202] [Citation(s) in RCA: 59] [Impact Index Per Article: 19.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2020] [Revised: 08/28/2020] [Accepted: 08/30/2020] [Indexed: 12/12/2022]
Abstract
Across Latin American and Caribbean countries (LACs), the fight against dementia faces pressing challenges, such as heterogeneity, diversity, political instability, and socioeconomic disparities. These can be addressed more effectively in a collaborative setting that fosters open exchange of knowledge. In this work, the Latin American and Caribbean Consortium on Dementia (LAC-CD) proposes an agenda for integration to deliver a Knowledge to Action Framework (KtAF). First, we summarize evidence-based strategies (epidemiology, genetics, biomarkers, clinical trials, nonpharmacological interventions, networking, and translational research) and align them to current global strategies to translate regional knowledge into transformative actions. Then we characterize key sources of complexity (genetic isolates, admixture in populations, environmental factors, and barriers to effective interventions), map them to the above challenges, and provide the basic mosaics of knowledge toward a KtAF. Finally, we describe strategies supporting the knowledge creation stage that underpins the translational impact of KtAF.
Collapse
Affiliation(s)
- Mario Alfredo Parra
- School of Psychological Sciences and HealthGraham Hills BuildingGlasgow, G1 1QE, UK, Universidad Autónoma del CaribePrograma de PsicologíaUniversity of StrathclydeBarranquillaColombia
| | | | - Lucas Sedeño
- Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET)Buenos AiresArgentina
| | - Cecilia Gonzalez Campo
- Cognitive Neuroscience Center (CNC)Universidad de San AndresConsejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET)Buenos AiresArgentina
| | - Hernando Santamaría‐García
- Pontificia Universidad JaverianaMedical School, Physiology and Psychiatry DepartmentsMemory and Cognition Center IntellectusHospital Universitario San IgnacioBogotáColombia
| | - Ivan Aprahamian
- Department of Internal MedicineFaculty of Medicine of JundiaíGroup of Investigation on Multimorbidity and Mental Health in Aging (GIMMA)JundiaíState of São PauloBrazil
| | - Paulo HF Bertolucci
- Department of Neurology and NeurosurgeryEscola Paulista de MedicinaFederal University of São Paulo ‐ UNIFESPSão PauloBrazil
| | - Julian Bustin
- INECO FoundationInstitute of Cognitive and Translational Neuroscience (INCYT)Favaloro UniversityBuenos AiresArgentina
| | | | - Carlos Cano‐Gutierrez
- Medical SchoolGeriatric Unit, Memory and Cognition Center‐IntellectusAging InstituteHospital Universitario San IgnacioPontificia Universidad JaverianaBogotáColombia
| | - Paulo Caramelli
- Faculdade de MedicinaUniversidade Federal de Minas GeraisBelo HorizonteBrazil
| | - Marcia L. F. Chaves
- Neurology ServiceHospital de Clínicas de Porto Alegre e Universidade Federal do Rio Grande do SulBrazil
| | - Patricia Cogram
- Laboratory of Molecular NeuropsychiatryINECO FoundationNational Scientific and Technical Research CouncilInstitute of Cognitive and Translational Neuroscience (INCyT)Favaloro UniversityBuenos AiresArgentina
| | - Bárbara Costa Beber
- Department of Speech and Language PathologyAtlantic Fellow for Equity in Brain HealthFederal University of Health Sciences of Porto Alegre (UFCSPA)Porto AlegreBrazil
| | - Felipe A. Court
- Center for Integrative BiologyFaculty of SciencesFONDAP Center for GeroscienceBrain Health and Metabolism, Santiago, Chile, The Buck Institute for Research on AgingUniversidad Mayor, ChileNovatoCAUSA
| | | | - Nilton Custodio
- Unit Cognitive Impairment and Dementia PreventionCognitive Neurology CenterPeruvian Institute of NeurosciencesLimaPerú
| | - Andres Damian
- Centro Uruguayo de Imagenología Molecular (CUDIM)Centro de Medicina Nuclear e Imagenología MolecularHospital de ClínicasUniversidad de la RepúblicaMontevideoUruguay
| | - Myriam de la Cruz
- Global Brain Health Institute, University of CaliforniaSan FranciscoUSA
| | - Roberta Diehl Rodriguez
- Behavioral and Cognitive Neurology UnitDepartment of Neurology and LIM 22University of São PauloSão PauloBrazil
| | | | - Lais Fajersztajn
- Laboratory of Experimental Air Pollution (LIM05)Department of PathologySchool of MedicineGlobal Brain Health Institute, University of CaliforniaSan Francisco (UCSF)University of São PauloSão PauloSao PauloBrazil
| | - Gonzalo A. Farías
- Department Neurology and Neurosurgery North/Department of NeurosciencesCenter for Advanced Clinical Research (CICA)Faculty of MedicineUniversidad de ChileSantiagoChile
| | | | - Raffaele Ferrari
- Department of Neurodegenerative DiseaseUniversity College LondonLondonESUK
| | - Fabricio Ferreira de Oliveira
- Department of Neurology and NeurosurgeryEscola Paulista de MedicinaFederal University of São Paulo ‐ UNIFESPSão PauloBrazil
| | - Sergio T. Ferreira
- Institute of Medical Biochemistry Leopoldo de Meis & Institute of Biophysics Carlos Chagas FilhoFederal University of Rio de JaneiroRio de JaneiroRJBrazil
| | - Ceres Ferretti
- Division of NeurologyUniversity of São PauloSão PauloBrazil
| | | | | | - Patricio Fuentes
- Geriatrics Section Clinical Hospital University of Chile, Santos Dumont 999 IndependenciaSantiagoChile
| | - Adolfo M. García
- Cognitive Neuroscience Center (CNC)Faculty of EducationNational University of Cuyo (UNCuyo)Universidad de San Andres. National Scientific and Technical Research Council (CONICET)MendozaArgentina
| | | | - Fábio Henrique de Gobbi Porto
- Laboratory of Psychiatric Neuroimaging (LIM‐21)Instituto de PsiquiatriaHospital das Clinicas HCFMUSPFaculdade de MedicinaUniversidade de Sao PauloSao PauloSao PauloBrazil
| | | | | | | | - Ignacio F. Mata
- Department of Genomic MedicineLerner Research InstituteCleveland ClinicOHUSA
| | - Christian Gonzalez‐Billault
- Center for GeroscienceBrain Health and Metabolism (GERO), Santiago, Chile, and Department of Biology, Faculty of SciencesUniversity of ChileSantiagoChile
| | - Oscar L. Lopez
- Alzheimer's Disease Research CenterUniversity of PittsburghPittsburghPAUSA
| | - Laura Morelli
- Fundacion Instituto Leloir‐IIBBA‐CONICET. AveArgentina
| | - Ricardo Nitrini
- Department of NeurologyUniversity of São Paulo Medical SchoolSão PauloBrazil
| | | | - Alejandra Guerrero Barragan
- Trinity College Dublin, Dublin, Departamento de Neurologia Hospital Occidente de KennedyGlobal Brain Health InstituteUniversidad de la SabanaBogotaColombia
| | - David Huepe
- Center for Social and Cognitive Neuroscience (CSCN)School of PsychologyUniversidad Adolfo IbañezSantiagoChile
| | - Fabricio Joao Pio
- Department of NeurologyHospital Governador Celso RamosFlorianopolisBrazil
| | | | - Renata Kochhann
- Graduate Program in PsychologySchool of Health SciencesHospital Moinhos de VentoPontifical Catholic University of Rio Grande do Sul—PUCRS and Researcher OfficePorto AlegreBrazil
| | - Silvia Kochen
- Neurosciences and Complex Systems Unit (EnyS), CONICET, Hosp, El Cruce “N. Kirchner”, Univ. National A, Jauretche (UNAJ), F. Varela, Prov. Buenos Aires. Fac. MedicineUniv Nacional de Buenos Aires (UBA)Buenos AiresArgentina
| | - Fiona Kumfor
- Brain and Mind Centre and School of PsychologyUniversity of SydneySydneyNSWAustralia
| | - Serggio Lanata
- UCSF Department of NeurologyMemory and Aging CenterUCSFSan FranciscoCaliforniaUS
| | - Bruce Miller
- UCSF Department of NeurologyMemory and Aging CenterUCSFSan FranciscoCaliforniaUS
| | | | - Mirna Lie Hosogi
- Behavioral and Cognitive Unit of Department of NeurologyUniversity of São Paulo School of MedicineSao PauloBrazil
| | - Patricia Lillo
- Geroscience Center for Brain Health and Metabolism, Santiago, Chile, Departamento de Neurología Sur/Departamento de Neurociencia, Facultad de MedicinaUniversidad de ChileSantiagoChile
| | | | - David Lira
- Unit Cognitive Impairment and Dementia PreventionCognitive Neurology CenterPeruvian Institute of NeurosciencesLimaPerú
| | - Francisco Lopera
- Neuroscience Research GroupUniversidad de AntioquiaMedellínColombia
| | - Adelina Comas
- Department of Health Policy at the London School of Economics and Political ScienceLondonUK
| | | | - Ana Luisa Sosa
- Instituto Nacional de Neurología y NeurocirugíaCiudad de MéxicoMéxico
| | - Claudia Ramos
- Global Brain Health Institute, University of California, San Francisco (UCSF)San FranciscoUSA
| | | | | | - Ioannis Tarnanas
- Global Brain Health Institute, University of CaliforniaSan FranciscoUSA
- Altoida Inc.HoustonTexasUSA
| | - Jenifer Yokoyama
- UCSF Department of NeurologyMemory and Aging CenterUCSFSan FranciscoCaliforniaUS
| | | | | | - Kate Possin
- UCSF Department of NeurologyMemory and Aging CenterUCSFSan FranciscoCaliforniaUS
| | - Kenneth S. Kosik
- Neuroscience Research Institute and Dept of Molecular Cellular and Developmental BiologyUniversity of California SantaBarbaraCaliforniaUSA
| | - Rosa Montesinos
- Unit Cognitive Impairment and Dementia PreventionCognitive Neurology CenterPeruvian Institute of NeurosciencesLimaPerú
| | - Sebastian Moguilner
- Global Brain Health Institute, University of California, San Francisco (UCSF)San FranciscoUSA
| | - Patricia Cristina Lourdes Solis
- Neurosciences and Complex Systems Unit (EnyS), CONICET, Hosp, El Cruce “N. Kirchner”, Univ. National A, Jauretche (UNAJ), F. Varela, Prov. Buenos Aires. Fac. MedicineUniv Nacional de Buenos Aires (UBA)Buenos AiresArgentina
| | | | - Jeronimo Martin Ramirez
- Departamen de Admision Continua Adultos Hospital General La Raza Instituto Mexicano del Seguro SocialGlobal Brain Health Institute, Trinity College Dublin, DublinCiudad de MexicoMexico
| | - Diana Matallana
- Medical SchoolAging Institute and Psychiatry DepartmentPontificia Universidad Javeriana. Memory and Cognition Center‐IntellectusHospital Universitario San IgnacioBogotáColombia
| | - Lingani Mbakile‐Mahlanza
- Global Brain Health InstituteUniversity of California San Francisco, University of BotswanaGaboroneBotswana
| | | | | | - Eliane C Miotto
- Department of NeurologyUniversity of Sao PauloSao PauloBrazil
| | | | | | - David Orozco
- Cognitive Neuroscience Development LaboratoryAxis NeurocienciasUniversidad Nacional del Sur, Cognitive Impairment and Behavior Disorders UnitBahía BlancaArgentina
| | - Maira Okada de Oliveira
- Global Brain Health Institute, University of California, San Francisco (UCSF)San FranciscoUSA
| | - Olivier Piguet
- School of Psychology and Brain and Mind CentreUniversity of SydneyCamperdownNSWAustralia
| | - Maritza Pintado Caipa
- Global Brain Health Institute, University of California, San Francisco (UCSF)San FranciscoUSA
| | | | - Lucas Porcello Schilling
- Department of NeurologyPontificia Universidade Catolica do Rio Grande do Sul (PUCRS)Porto AlegreBrazil
| | - André Luiz Rodrigues Palmeira
- Santa Casa de Misericórdia de Porto Alegre, Serviço de Neurologia, Porto Alegre, BrazilHospital Ernesto DornellesServiço de Neurologia e NeurocirurgiaPorto AlegreBrazil
| | | | - Jose Manuel Santacruz‐Escudero
- Medical School and Psychiatry DepartmentMemory and Cognition Center‐ IntellectusPontificia Universidad JaverianaHospital Universitario San IgnacioBogotáColombia
| | | | - Jerusa Smid
- Department of NeurologyUniversity of Sao PauloSão PauloBrazil
| | - Andrea Slachevsky
- Neurology DepartmentGeroscience Center for Brain Health and Metabolism, Santiago, Chile, Laboratory of Neuropsychology and Clinical Neuroscience (LANNEC), Physiopathology Program‐ICBM, East Neurologic and Neurosciences Departments, Faculty of MedicineHospital del Salvador and Faculty of Medicine University of Chile. Servicio de NeurologíaDepartamento de MedicinaClínica Alemana—Universidad del DesarrolloUniversity of Chile, Neuropsychiatry and Memory Disorders clinic (CMYN)SantiagoChile
| | | | | | | | - Lea Tenenholz Grinberg
- Departments of NeurologyPathology and Global Brain Health InstituteUCSF ‐ USA, Department of PathologyUniversity of São Paulo Medical SchoolSão PauloBrazil
| | - Antonio Lucio Teixeira
- Laboratório Interdisciplinar de Investigação MédicaFaculdade de MedicinaAv. Alfredo Balena, 110Universidade Federal de Minas GeraisBelo HorizonteBrazil
| | - Maira Tonidandel Barbosa
- Faculdade de Medicina da Universidade Federal de Minas Gerais e Faculdade deCiências Médicas de Minas GeraisBelo HorizonteBrazil
| | - Dominic Trépel
- Global Brain Health Institute (GBHI)Trinity College DublinDublin
| | - Agustin Ibanez
- Cognitive Neuroscience Center (CNC) Buenos Aires, Argentina; Universidad Autonoma del Caribe, Barranquilla, Colombia; Global Brain Health Institute (GBHI), USUniversidad de San AndresCONICETUniversidad Autonoma del CaribeUniversidad Adolfo IbanezUCSFUSA
| |
Collapse
|
18
|
Consequence of stroke for feature recall and binding in visual working memory. Neurobiol Learn Mem 2021; 179:107387. [PMID: 33460791 DOI: 10.1016/j.nlm.2021.107387] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2020] [Revised: 12/20/2020] [Accepted: 01/10/2021] [Indexed: 11/20/2022]
Abstract
Visual memory for objects involves the integration, or binding, of individual features into a coherent representation. We used a novel approach to assess feature binding, using a delayed-reproduction task in combination with computational modeling and lesion analysis. We assessed stroke patients and neurotypical controls on a visual working memory task in which spatial arrays of colored disks were presented. After a brief delay, participants either had to report the color of one disk cued by its location or the location of one disk cued by its color. Our results demonstrate that, in the controls, report imprecision and swap errors (non-target reports) can be explained by a single source of variability. Stroke patients showed an overall decrease in memory precision for both color and location, with only limited evidence for deviations from the predicted relationship between report precision and swap errors. These deviations were primarily deficits in reporting items rather than selecting items based on the cue. Atlas-based lesion-symptom mapping showed that selection and reporting deficits, precision in reporting color, and precision in reporting location were associated with different lesion profiles. Deficits in binding are associated with lesions in the left somatosensory cortex, deficits in the precision of reporting color with bilateral fronto-parietal regions, and no anatomical substrates were identified for precision in reporting location. Our results converge with previous reports that working memory representations are widely distributed in the brain and can be found across sensory, parietal, temporal, and prefrontal cortices. Stroke patients demonstrate mostly subtle impairments in visual working memory, perhaps because representations from different areas in the brain can partly compensate for impaired encoding in lesioned areas. These findings contribute to understanding of the relation between memorizing features and their bound representations.
Collapse
|
19
|
Zokaei N, Sillence A, Kienast A, Drew D, Plant O, Slavkova E, Manohar SG, Husain M. Different patterns of short-term memory deficit in Alzheimer's disease, Parkinson's disease and subjective cognitive impairment. Cortex 2020; 132:41-50. [PMID: 32919108 PMCID: PMC7651994 DOI: 10.1016/j.cortex.2020.06.016] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2020] [Revised: 05/25/2020] [Accepted: 06/23/2020] [Indexed: 01/06/2023]
Abstract
It has recently been proposed that short-term memory (STM) binding deficits might be an important feature of Alzheimer's disease (AD), providing a potential avenue for earlier detection of this disorder. By contrast, work in Parkinson's disease (PD), using different tasks, has suggested that the STM impairment in this condition is characterised by increased random guessing, possibly due to fluctuating attention. In the present study, to establish whether a misbinding impairment is present in sporadic late-onset AD (LOAD) and increased guessing is a feature of PD, we compared the performance of these patient groups to two control populations: healthy age-matched controls and individuals with subjective cognitive impairment (SCI) with comparable recruitment history as patients. All participants performed a sensitive task of STM that required high resolution retention of object-location bindings. This paradigm also enabled us to explore the underlying sources of error contributing to impaired STM in patients with LOAD and PD using computational modelling of response error. Patients with LOAD performed significantly worse than other groups on this task. Importantly their impaired memory was associated with increased misbinding errors. This was in contrast to patients with PD who made significantly more guessing responses. These findings therefore provide additional support for the presence of two doubly dissociable signatures of STM deficit in AD and PD, with binding impairment in AD and increased random guessing characterising the STM deficit in PD. The task used to measure memory precision here provides an easy-to-administer assessment of STM that is sensitive to the different types of deficit in AD and PD and hence has the potential to inform clinical practice.
Collapse
Affiliation(s)
- Nahid Zokaei
- Oxford Centre for Human Brain Activity, Wellcome Centre for Integrative Neuroimaging, Department of Psychiatry, University of Oxford, Oxford, OX3 7JX, UK; Department of Experimental Psychology, University of Oxford, Oxford, OX1 3UD, UK.
| | - Annie Sillence
- Department of Experimental Psychology, University of Oxford, Oxford, OX1 3UD, UK
| | - Annika Kienast
- Department of Experimental Psychology, University of Oxford, Oxford, OX1 3UD, UK
| | - Daniel Drew
- Department of Experimental Psychology, University of Oxford, Oxford, OX1 3UD, UK; Wellcome Centre for Integrative Neuroimaging, John Radcliffe Hospital, Oxford, UK
| | - Olivia Plant
- Department of Experimental Psychology, University of Oxford, Oxford, OX1 3UD, UK
| | - Ellie Slavkova
- Department of Experimental Psychology, University of Oxford, Oxford, OX1 3UD, UK
| | - Sanjay G Manohar
- Oxford NIHR Biomedical Research Centre, UK; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, OX3 9DU, UK
| | - Masud Husain
- Department of Experimental Psychology, University of Oxford, Oxford, OX1 3UD, UK; Oxford NIHR Biomedical Research Centre, UK; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, OX3 9DU, UK
| |
Collapse
|
20
|
Franco-Macías E, Rodrigo-Herrero S, Luque-Tirado A, Méndez-Barrio C, Medina-Rodriguez M, Graciani-Cantisán E, Sánchez-Arjona MB, Maillet D. Reliability and Feasibility of the Memory Associative Test TMA-93. J Alzheimers Dis Rep 2020; 4:431-440. [PMID: 33283164 PMCID: PMC7683101 DOI: 10.3233/adr-200215] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/20/2020] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Memory tests focused on binding may be more sensitive to diagnose Alzheimer's disease (AD) at an early phase. TMA-93 examines relational binding by images. OBJECTIVE Evaluate the reliability (internal consistency and inter-rater and test-retest reliability) and feasibility of the TMA-93 in a clinic setting with low-educated individuals and limited face-to-face time per patient. METHODS The study was undertaken in a neurology outpatient clinic of a hospital in Southern Spain. The internal consistency of the TMA-93 was estimated in 35 patients with amnestic mild cognitive impairment (aMCI) and 40 healthy controls (HCs). The inter-rater reliability (by two raters) and feasibility (by recording the percentage of participants who completed the test, and by timing the administration time) were evaluated in HCs (n = 16), aMCI patients (n = 18), and mild dementia patients (n = 15). The test-retest reliability for the TMA-93 total score was studied in 51 HCs tested by the same examiner 2-4 months apart. The internal consistency was estimated by Cronbach's alpha. The inter-rater and test-retest reliability was quantified by the intraclass correlation coefficient (ICC). The administration time was compared by diagnosis. RESULTS The internal consistency was "optimal" (Cronbach's alpha = 0.936). The test-retest reliability was "good" [ICC = 0.802 (CI 95% = 0.653-0.887)]. The inter-rater reliability was "optimal" [ICC = 0.999, (CI 95% = 0.999-1)]. All participants completed the test. The administration time ranged from less than 3 min in HCs to 6 min in aMCI patients, and 7 min in mild dementia patients. CONCLUSION Good feasibility and reliability support using the TMA-93 for examining visual relational binding, particularly in the context of low-educational attainment and limited time per patient.
Collapse
Affiliation(s)
- Emilio Franco-Macías
- Unidad de Memoria, Servicio de Neurología, Hospital Universitario Virgen del Rocío, Seville, Spain
| | - Silvia Rodrigo-Herrero
- Unidad de Memoria. Servicio de Neurología, Hospital Universitario Juan Ramón Jiménez, Huelva, Spain
| | - Andrea Luque-Tirado
- Unidad de Memoria, Servicio de Neurología, Hospital Universitario Virgen del Rocío, Seville, Spain
| | - Carlota Méndez-Barrio
- Unidad de Memoria. Servicio de Neurología, Hospital Universitario Juan Ramón Jiménez, Huelva, Spain
| | - Manuel Medina-Rodriguez
- Unidad de Memoria, Servicio de Neurología, Hospital Universitario Virgen del Rocío, Seville, Spain
| | | | | | - Didier Maillet
- Service de Neurologie, Hôpital Saint-Louis (AP-HP), Paris, France
| |
Collapse
|
21
|
Gelman S, Palma J, Ghavami A. Axonal Conduction Velocity in CA1 Area of Hippocampus is Reduced in Mouse Models of Alzheimer's Disease. J Alzheimers Dis 2020; 77:1383-1388. [PMID: 32925062 DOI: 10.3233/jad-200661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The timing of action potentials arrival at synaptic terminals partially determines integration of synaptic inputs and is important for information processing in the CNS. Therefore, axonal conduction velocity (VC) is a salient parameter, influencing the timing of synaptic inputs. Even small changes in VC may disrupt information coding in networks requiring accurate timing. We recorded compound action potentials in hippocampal slices to measure VC in three mouse models of Alzheimer's disease. We report an age-dependent reduction in VC in area CA1 in two amyloid-β precursor protein transgenic mouse models, line 41 and APP/PS1, and in a tauopathy model, rTg4510.
Collapse
|
22
|
Norton DJ, Parra MA, Sperling RA, Baena A, Guzman-Velez E, Jin DS, Andrea N, Khang J, Schultz A, Rentz DM, Pardilla-Delgado E, Fuller J, Johnson K, Reiman EM, Lopera F, Quiroz YT. Visual short-term memory relates to tau and amyloid burdens in preclinical autosomal dominant Alzheimer's disease. ALZHEIMERS RESEARCH & THERAPY 2020; 12:99. [PMID: 32825838 PMCID: PMC7442980 DOI: 10.1186/s13195-020-00660-z] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/19/2020] [Accepted: 07/28/2020] [Indexed: 11/15/2022]
Abstract
Background Over the past decade, visual short-term memory (VSTM) binding tests have been shown to be one of the most sensitive behavioral indicators of Alzheimer’s disease (AD), especially when they require the binding of multiple features (e.g., color and shape). Recently, it has become possible to directly measure amyloid and tau levels in vivo via positron emission tomography (PET). To this point, these behavioral and neurochemical markers have not been compared in humans with AD or at risk for it. Methods In a cross-sectional study, we compared VSTM performance to tau and amyloid concentrations, measured by PET, in individuals certain to develop AD by virtue of their inheritance of the presenilin-1 E280A mutation. These included 21 clinically unimpaired subjects and 7 subjects with early mild cognitive impairment (MCI), as well as 30 family members who were not carriers of the mutation. Results We found that VSTM performance correlated strongly with tau in entorhinal cortex and inferior temporal lobe, and also with amyloid when examining asymptomatic carriers only. The condition requiring binding was not preferentially linked to tau—in fact, the non-binding “shape only” condition showed a stronger relationship. Conclusions The results confirm VSTM’s status as an early marker of AD pathology and raise interesting questions as to the course of binding-specific versus non-binding aspects of VSTM in early AD.
Collapse
Affiliation(s)
- Daniel J Norton
- Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 149 13th Street, Rm 10.014, Boston, MA, 02129, USA.,Gordon College, Wenham, MA, USA
| | - Mario A Parra
- School of Psychological Sciences and Health, University of Strathclyde, Glasgow, UK.,Autonomous University of the Caribbean, Barranquilla, Colombia
| | - Reisa A Sperling
- Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 149 13th Street, Rm 10.014, Boston, MA, 02129, USA.,Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, MA, USA.,Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Ana Baena
- Grupo de Neurociencias, Universidad de Antioquia, Medellin, Antioquia, Colombia
| | - Edmarie Guzman-Velez
- Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 149 13th Street, Rm 10.014, Boston, MA, 02129, USA
| | - David S Jin
- Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 149 13th Street, Rm 10.014, Boston, MA, 02129, USA
| | - Nicholas Andrea
- Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 149 13th Street, Rm 10.014, Boston, MA, 02129, USA
| | | | - Aaron Schultz
- Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 149 13th Street, Rm 10.014, Boston, MA, 02129, USA.,Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, MA, USA
| | - Dorene M Rentz
- Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 149 13th Street, Rm 10.014, Boston, MA, 02129, USA
| | - Enmanuelle Pardilla-Delgado
- Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 149 13th Street, Rm 10.014, Boston, MA, 02129, USA
| | - Joshua Fuller
- Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 149 13th Street, Rm 10.014, Boston, MA, 02129, USA
| | - Keith Johnson
- Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 149 13th Street, Rm 10.014, Boston, MA, 02129, USA.,Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, MA, USA
| | | | - Francisco Lopera
- Grupo de Neurociencias, Universidad de Antioquia, Medellin, Antioquia, Colombia
| | - Yakeel T Quiroz
- Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 149 13th Street, Rm 10.014, Boston, MA, 02129, USA. .,Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, MA, USA. .,Grupo de Neurociencias, Universidad de Antioquia, Medellin, Antioquia, Colombia. .,Departments of Psychiatry and Neurology, Massachusetts General Hospital, Harvard Medical School, 149 13th Street, Rm 10.014, Boston, MA, 02129, USA.
| |
Collapse
|
23
|
Fuller JT, Cronin-Golomb A, Gatchel JR, Norton DJ, Guzmán-Vélez E, Jacobs HIL, Hanseeuw B, Pardilla-Delgado E, Artola A, Baena A, Bocanegra Y, Kosik KS, Chen K, Tariot PN, Johnson K, Sperling RA, Reiman EM, Lopera F, Quiroz YT. Biological and Cognitive Markers of Presenilin1 E280A Autosomal Dominant Alzheimer's Disease: A Comprehensive Review of the Colombian Kindred. JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE 2020; 6:112-120. [PMID: 30756118 DOI: 10.14283/jpad.2019.6] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The study of individuals with autosomal dominant Alzheimer's disease affords one of the best opportunities to characterize the biological and cognitive changes of Alzheimer's disease that occur over the course of the preclinical and symptomatic stages. Unifying the knowledge gained from the past three decades of research in the world's largest single-mutation autosomal dominant Alzheimer's disease kindred - a family in Antioquia, Colombia with the E280A mutation in the Presenilin1 gene - will provide new directions for Alzheimer's research and a framework for generalizing the findings from this cohort to the more common sporadic form of Alzheimer's disease. As this specific mutation is virtually 100% penetrant for the development of the disease by midlife, we use a previously defined median age of onset for mild cognitive impairment for this cohort to examine the trajectory of the biological and cognitive markers of the disease as a function of the carriers' estimated years to clinical onset. Studies from this cohort suggest that structural and functional brain abnormalities - such as cortical thinning and hyperactivation in memory networks - as well as differences in biofluid and in vivo measurements of Alzheimer's-related pathological proteins distinguish Presenilin1 E280A mutation carriers from non-carriers as early as childhood, or approximately three decades before the median age of onset of clinical symptoms. We conclude our review with discussion on future directions for Alzheimer's disease research, with specific emphasis on ways to design studies that compare the generalizability of research in autosomal dominant Alzheimer's disease to the larger sporadic Alzheimer's disease population.
Collapse
Affiliation(s)
- J T Fuller
- Yakeel T. Quiroz, PhD Assistant Professor, Harvard Medical School, Departments of Psychiatry and Neurology, Massachusetts General Hospital, 100 1st Avenue, Building 39, Suite 101, Charlestown, MA 02129, Phone (617) 643-5944; Fax: (617) 726-5760, E-mail:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Harrison JR, Bhatia S, Tan ZX, Mirza-Davies A, Benkert H, Tax CMW, Jones DK. Imaging Alzheimer's genetic risk using diffusion MRI: A systematic review. Neuroimage Clin 2020; 27:102359. [PMID: 32758801 PMCID: PMC7399253 DOI: 10.1016/j.nicl.2020.102359] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2019] [Revised: 06/20/2020] [Accepted: 07/20/2020] [Indexed: 12/14/2022]
Abstract
Diffusion magnetic resonance imaging (dMRI) is an imaging technique which probes the random motion of water molecules in tissues and has been widely applied to investigate changes in white matter microstructure in Alzheimer's Disease. This paper aims to systematically review studies that examined the effect of Alzheimer's risk genes on white matter microstructure. We assimilated findings from 37 studies and reviewed their diffusion pre-processing and analysis methods. Most studies estimate the diffusion tensor (DT) and compare derived quantitative measures such as fractional anisotropy and mean diffusivity between groups. Those with increased AD genetic risk are associated with reduced anisotropy and increased diffusivity across the brain, most notably the temporal and frontal lobes, cingulum and corpus callosum. Structural abnormalities are most evident amongst those with established Alzheimer's Disease. Recent studies employ signal representations and analysis frameworks beyond DT MRI but show that dMRI overall lacks specificity to disease pathology. However, as the field advances, these techniques may prove useful in pre-symptomatic diagnosis or staging of Alzheimer's disease.
Collapse
Affiliation(s)
- Judith R Harrison
- Cardiff University Brain Research Imaging Centre (CUBRIC), Maindy Road, Cardiff CF24 4HQ, UK.
| | - Sanchita Bhatia
- Cardiff University School of Medicine, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, UK
| | - Zhao Xuan Tan
- Cardiff University School of Medicine, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, UK
| | - Anastasia Mirza-Davies
- Cardiff University School of Medicine, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, UK
| | - Hannah Benkert
- Cardiff University School of Medicine, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, UK
| | - Chantal M W Tax
- Cardiff University Brain Research Imaging Centre (CUBRIC), Maindy Road, Cardiff CF24 4HQ, UK
| | - Derek K Jones
- Cardiff University Brain Research Imaging Centre (CUBRIC), Maindy Road, Cardiff CF24 4HQ, UK; Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, VIC, Australia
| |
Collapse
|
25
|
Velásquez-Torres A, Díaz-Forero A, Talero-Gutiérrez C. The Insomnia Plague in Fictional Macondo. Perm J 2020; 24:19.192. [PMID: 32663127 DOI: 10.7812/tpp/19.192] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Disease and medicine are found throughout Gabriel García Márquez's work. This article examines the insomnia plague described in the novel One Hundred Years of Solitude and performs a differential diagnosis exercise with conditions that affect both sleep and memory. The main finding is that the insomnia plague narrated by García Márquez, with its clinical manifestations, the sequence of symptoms, and its resolution, cannot be associated with any specific diagnosis. However, similarities to and differences from several clinical conditions are discussed, as well as the relation between the neurophysiologic phenomena of sleep and memory.
Collapse
Affiliation(s)
- Alejandro Velásquez-Torres
- Neuroscience Research Group Neuros, Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogota, Colombia
| | - Andrés Díaz-Forero
- Undergraduate Neuroscience Research Group Semineuros, Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogota, Colombia
| | - Claudia Talero-Gutiérrez
- Neuroscience Research Group Neuros, Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogota, Colombia
| |
Collapse
|
26
|
Ponomareva N, Andreeva T, Protasova M, Konovalov R, Krotenkova M, Malina D, Mitrofanov A, Fokin V, Illarioshkin S, Rogaev E. Genetic Association Between Alzheimer's Disease Risk Variant of the PICALM Gene and EEG Functional Connectivity in Non-demented Adults. Front Neurosci 2020; 14:324. [PMID: 32372909 PMCID: PMC7177435 DOI: 10.3389/fnins.2020.00324] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2019] [Accepted: 03/19/2020] [Indexed: 11/13/2022] Open
Abstract
Genome wide association studies (GWAS) have identified and validated the association of the PICALM genotype with Alzheimer's disease (AD). The PICALM rs3851179 A allele is thought to have a protective effect, whereas the G allele appears to confer risk for AD. The influence of the PICALM genotype on brain functional connectivity in non-demented subjects remains largely unknown. We examined the association of the PICALM rs3851179 genotype with the characteristics of lagged linear connectivity (LLC) of resting EEG sources in 104 non-demented adults younger than 60 years of age. The EEG analysis was performed using exact low-resolution brain electromagnetic tomography (eLORETA) freeware (Pascual-Marqui et al., 2011). We found that the carriers of the A PICALM allele (PICALM AA and AG genotypes) had higher widespread interhemispheric LLC of alpha sources compared to the carriers of the GG PICALM allele. An exploratory correlation analysis showed a moderate positive association between the alpha LLC interhemispheric characteristics and the corpus callosum size and between the alpha interhemispheric LLC characteristics and the Luria word memory scores. These results suggest that the PICALM rs3851179 A allele provides protection against cognitive decline by facilitating neurophysiological reserve capacities in non-demented adults. In contrast, lower functional connectivity in carriers of the AD risk variant, PICALM GG, suggests early functional alterations in alpha rhythm networks.
Collapse
Affiliation(s)
- Natalya Ponomareva
- Research Center of Neurology, Russian Academy of Sciences, Moscow, Russia
| | - Tatiana Andreeva
- Laboratory of Evolutionary Genomics, Department of Human Genetics and Genomics, Vavilov Institute of General Genetics, Russian Academy of Sciences, Moscow, Russia.,Center for Genetics and Genetic Technologies, Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia
| | - Maria Protasova
- Laboratory of Evolutionary Genomics, Department of Human Genetics and Genomics, Vavilov Institute of General Genetics, Russian Academy of Sciences, Moscow, Russia
| | - Rodion Konovalov
- Research Center of Neurology, Russian Academy of Sciences, Moscow, Russia
| | - Marina Krotenkova
- Research Center of Neurology, Russian Academy of Sciences, Moscow, Russia
| | - Daria Malina
- Research Center of Neurology, Russian Academy of Sciences, Moscow, Russia
| | - Andrey Mitrofanov
- Research Center of Mental Health, Russian Academy of Medical Sciences, Moscow, Russia
| | - Vitaly Fokin
- Research Center of Neurology, Russian Academy of Sciences, Moscow, Russia
| | | | - Evgeny Rogaev
- Laboratory of Evolutionary Genomics, Department of Human Genetics and Genomics, Vavilov Institute of General Genetics, Russian Academy of Sciences, Moscow, Russia.,Center for Genetics and Genetic Technologies, Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia.,Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA, United States.,Sirius University of Science and Technology, Sochi, Russia
| |
Collapse
|
27
|
Luo C, Li M, Qin R, Chen H, Yang D, Huang L, Liu R, Xu Y, Bai F, Zhao H. White Matter Microstructural Damage as an Early Sign of Subjective Cognitive Decline. Front Aging Neurosci 2020; 11:378. [PMID: 32047428 PMCID: PMC6997435 DOI: 10.3389/fnagi.2019.00378] [Citation(s) in RCA: 38] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2019] [Accepted: 12/23/2019] [Indexed: 01/21/2023] Open
Abstract
Background and Objective: Subjective cognitive decline (SCD) is considered a preclinical state of Alzheimer's disease (AD) and may represent a more advanced preclinical status than amnestic mild cognitive impairment (aMCI). Our aim was to explore changes in the white matter (WM) microstructure and their correlation with cognitive function in these AD-spectrum patients. Methods: Diffusion tensor images from 43 individuals with normal cognition (NC), 38 SCD patients, and 36 aMCI patients were compared using an atlas-based segmentation strategy. The correlation between diffusion parameters and cognitive function was further analyzed. Results: The anatomical pattern of WM impairment was generally similar between SCD and aMCI patients. However, aMCI patients showed significantly lower fractional anisotropy (i.e., corpus callosum forceps major and forceps minor) and increased mean diffusivity [i.e., bilateral anterior thalamic radiation (ATR), left corticospinal tract (CST), forceps minor, left cingulum (cingulate gyrus), left cingulum hippocampus, and left inferior fronto-occipital fasciculus (IFO)] in some tracts than did SCD subjects, indicating a disruption in WM microstructural integrity in the aMCI. Individuals with microstructural disruption in forceps minor, left cingulum (cingulate gyrus), and left cingulum hippocampus tracts performed worse in general cognition and memory function tests, as indicated by line regression analysis. Conclusion: SCD individuals had extensive WM microstructural damage in a pattern similar to that seen in aMCI, although presenting a cognitive performance comparable with that of cognitively healthy individuals. Our results suggest that WM integrity might precede objectively measurable memory decline and may be a potential early biomarker for AD.
Collapse
Affiliation(s)
- Caimei Luo
- Department of Neurology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, China.,Jiangsu Key Laboratory for Molecular Medicine, Nanjing University Medical School, Nanjing, China.,Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing, China.,Nanjing Neuropsychiatry Clinic Medical Center, Nanjing, China
| | - Mengchun Li
- Department of Neurology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, China.,Jiangsu Key Laboratory for Molecular Medicine, Nanjing University Medical School, Nanjing, China.,Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing, China.,Nanjing Neuropsychiatry Clinic Medical Center, Nanjing, China
| | - Ruomeng Qin
- Department of Neurology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, China.,Jiangsu Key Laboratory for Molecular Medicine, Nanjing University Medical School, Nanjing, China.,Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing, China.,Nanjing Neuropsychiatry Clinic Medical Center, Nanjing, China
| | - Haifeng Chen
- Department of Neurology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, China.,Jiangsu Key Laboratory for Molecular Medicine, Nanjing University Medical School, Nanjing, China.,Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing, China.,Nanjing Neuropsychiatry Clinic Medical Center, Nanjing, China
| | - Dan Yang
- Department of Neurology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, China.,Jiangsu Key Laboratory for Molecular Medicine, Nanjing University Medical School, Nanjing, China.,Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing, China.,Nanjing Neuropsychiatry Clinic Medical Center, Nanjing, China
| | - Lili Huang
- Department of Neurology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, China.,Jiangsu Key Laboratory for Molecular Medicine, Nanjing University Medical School, Nanjing, China.,Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing, China.,Nanjing Neuropsychiatry Clinic Medical Center, Nanjing, China
| | - Renyuan Liu
- Department of Neurology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, China.,Jiangsu Key Laboratory for Molecular Medicine, Nanjing University Medical School, Nanjing, China.,Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing, China.,Nanjing Neuropsychiatry Clinic Medical Center, Nanjing, China
| | - Yun Xu
- Department of Neurology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, China.,Jiangsu Key Laboratory for Molecular Medicine, Nanjing University Medical School, Nanjing, China.,Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing, China.,Nanjing Neuropsychiatry Clinic Medical Center, Nanjing, China
| | - Feng Bai
- Department of Neurology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, China.,Jiangsu Key Laboratory for Molecular Medicine, Nanjing University Medical School, Nanjing, China.,Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing, China.,Nanjing Neuropsychiatry Clinic Medical Center, Nanjing, China
| | - Hui Zhao
- Department of Neurology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, China.,Jiangsu Key Laboratory for Molecular Medicine, Nanjing University Medical School, Nanjing, China.,Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing, China.,Nanjing Neuropsychiatry Clinic Medical Center, Nanjing, China
| |
Collapse
|
28
|
The striatum, the hippocampus, and short-term memory binding: Volumetric analysis of the subcortical grey matter's role in mild cognitive impairment. NEUROIMAGE-CLINICAL 2019; 25:102158. [PMID: 31918064 PMCID: PMC7036699 DOI: 10.1016/j.nicl.2019.102158] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/18/2019] [Revised: 12/27/2019] [Accepted: 12/28/2019] [Indexed: 12/14/2022]
Abstract
Hippocampal atrophy plays no role in short-term memory binding. The globus pallidus could be part of the brain network supporting binding. Total brain atrophy does not correlate with striatal grey matter atrophy in MCI. Striatal grey matter atrophy reflects in total brain atrophy in controls. Hippocampal and parahippocampal volumes correlate in MCI and controls.
Background Deficits in short-term memory (STM) binding are a distinguishing feature of preclinical stages leading to Alzheimer's disease (AD). However, the neuroanatomical correlates of conjunctive STM binding are largely unexplored. Here we examine the possible association between the volumes of hippocampi, parahippocampal gyri, and grey matter within the subcortical structures – all found to have foci that seemingly correlate with basic daily living activities in AD patients - with cognitive tests related to conjunctive STM binding. Materials and methods Hippocampal, thalamic, parahippocampal and corpus striatum volumes were semi-automatically quantified in brain magnetic resonance images from 25 cognitively normal people and 21 patients with Mild Cognitive Impairment (MCI) at high risk of AD progression, who undertook a battery of cognitive tests and the short-term memory binding test. Associations were assessed using linear regression models and group differences were assessed using the Mann-Whitney U test. Results Hippocampal and parahippocampal gyrus volumes differed between MCI and control groups. Although the grey matter volume in the globus pallidus (r = -0.71, p < 0.001) and parahippocampal gyry (r = -0.63, p < 0.05) correlated with a STM binding task in the MCI group, only the former remained associated with STM binding deficits in MCI patients, after correcting for age, gender and years of education (β = -0.56,P = 0.042) although with borderline significance. Conclusions Loss of hippocampal volume plays no role in the processing of STM binding. Structures within the basal ganglia, namely the globus pallidus, could be part of the extrahippocampal network supporting binding. Replication of this study in large samples is now needed.
Collapse
|
29
|
Serum amyloid A1 is involved in amyloid plaque aggregation and memory decline in amyloid beta abundant condition. Transgenic Res 2019; 28:499-508. [PMID: 31407125 DOI: 10.1007/s11248-019-00166-x] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2018] [Accepted: 08/02/2019] [Indexed: 01/21/2023]
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder, characterized by cognitive impairment, progressive neurodegeneration, and amyloid-β (Aβ) lesion. In the neuronal death and disease progression, inflammation is known to play an important role. Our previous study on acute-phase protein serum amyloid A1 (SAA1) overexpressed mice showed that the liver-derived SAA1 accumulated in the brain by crossing the brain blood barrier (BBB) and trigger the depressive-like behavior on mouse. Since SAA1 involved in immune responses in other diseases, we focused on the possibility that SAA1 may exacerbate the neuronal inflammation related to Alzheimer's disease. A APP/SAA overexpressed double transgenic mouse was generated using amyloid precursor protein overexpressed (APP)-c105 mice and SAA1 overexpressed mice to examine the function of SAA1 in Aβ abundant condition. Comparisons between APP and APP/SAA1 transgenic mice showed that SAA1 exacerbated amyloid aggregation and glial activation; which lead to the memory decline. Behavior tests also supported this result. Overall, overexpression of SAA1 intensified the neuronal inflammation in amyloid abundant condition and causes the greater memory decline compared to APP mice, which only expresses Aβ 1-42.
Collapse
|
30
|
Fallon SJ, Gowell M, Maio MR, Husain M. Dopamine affects short-term memory corruption over time in Parkinson's disease. NPJ Parkinsons Dis 2019; 5:16. [PMID: 31396548 PMCID: PMC6683156 DOI: 10.1038/s41531-019-0088-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2019] [Accepted: 06/25/2019] [Indexed: 11/09/2022] Open
Abstract
Cognitive deficits are a recognised component of Parkinson's disease (PD). However, particularly within the domain of short-term memory, it is unclear whether these impairments are masked, or caused, by patients' dopaminergic medication. The effect of medication on pure maintenance in PD patients has rarely been explored, with most assessments examining maintenance intercalated between other executive tasks. Moreover, few studies have utilised methods that can measure the quality of mental representations, which can enable the decomposition of recall errors into their underlying neurocognitive components. Here, we fill this gap by examining pure maintenance in PD patients in high and low dopaminergic states. Participants had to encode the orientation of two stimuli and reproduce these orientations after a short (2 s) or long (8 s) delay. In addition, we also examined the performance of healthy, age-matched older adults to contextualise these effects and determine whether PD represents an exacerbation of the normal ageing process. Patients showed improved recall OFF compared to ON their dopaminergic medication, but only for long-duration trials. Moreover, PD patients OFF their medication actually performed at a level superior to age-matched controls, indicative of a paradoxical enhancement of memory in the low dopaminergic state. The application of a probabilistic model of response selection suggested that PD patients made fewer misbinding errors in the low, compared with high, dopaminergic state for longer-delay trials. Thus, unexpectedly, the mechanisms that prevent memoranda from being corrupted by misbinding over time appear to be enhanced in PD patients OFF dopaminergic medication. Possible explanations for this paradoxical effect are discussed.
Collapse
Affiliation(s)
- Sean James Fallon
- Department of Experimental Psychology, University of Oxford, Oxford, UK
- National Institute for Health Research Bristol Biomedical Research Centre, University Hospitals Bristol NHS Foundation Trust and University of Bristol, Bristol, UK
| | - Matthew Gowell
- Department of Experimental Psychology, University of Oxford, Oxford, UK
| | - Maria Raquel Maio
- Department of Experimental Psychology, University of Oxford, Oxford, UK
| | - Masud Husain
- Department of Experimental Psychology, University of Oxford, Oxford, UK
- Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK
| |
Collapse
|
31
|
Araque Caballero MÁ, Suárez-Calvet M, Duering M, Franzmeier N, Benzinger T, Fagan AM, Bateman RJ, Jack CR, Levin J, Dichgans M, Jucker M, Karch C, Masters CL, Morris JC, Weiner M, Rossor M, Fox NC, Lee JH, Salloway S, Danek A, Goate A, Yakushev I, Hassenstab J, Schofield PR, Haass C, Ewers M. White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer's disease. Brain 2019; 141:3065-3080. [PMID: 30239611 PMCID: PMC6158739 DOI: 10.1093/brain/awy229] [Citation(s) in RCA: 102] [Impact Index Per Article: 20.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2018] [Accepted: 07/20/2018] [Indexed: 12/30/2022] Open
Abstract
White matter alterations are present in the majority of patients with Alzheimer's disease type dementia. However, the spatiotemporal pattern of white matter changes preceding dementia symptoms in Alzheimer's disease remains unclear, largely due to the inherent diagnostic uncertainty in the preclinical phase and increased risk of confounding age-related vascular disease and stroke in late-onset Alzheimer's disease. In early-onset autosomal-dominantly inherited Alzheimer's disease, participants are destined to develop dementia, which provides the opportunity to assess brain changes years before the onset of symptoms, and in the absence of ageing-related vascular disease. Here, we assessed mean diffusivity alterations in the white matter in 64 mutation carriers compared to 45 non-carrier family non-carriers. Using tract-based spatial statistics, we mapped the interaction of mutation status by estimated years from symptom onset on mean diffusivity. For major atlas-derived fibre tracts, we determined the earliest time point at which abnormal mean diffusivity changes in the mutation carriers were detectable. Lastly, we assessed the association between mean diffusivity and cerebrospinal fluid biomarkers of amyloid, tau, phosphorylated-tau, and soluble TREM2, i.e. a marker of microglia activity. Results showed a significant interaction of mutations status by estimated years from symptom onset, i.e. a stronger increase of mean diffusivity, within the posterior parietal and medial frontal white matter in mutation carriers compared with non-carriers. The earliest increase of mean diffusivity was observed in the forceps major, forceps minor and long projecting fibres-many connecting default mode network regions-between 5 to 10 years before estimated symptom onset. Higher mean diffusivity in fibre tracts was associated with lower grey matter volume in the tracts' projection zones. Global mean diffusivity was correlated with lower cerebrospinal fluid levels of amyloid-β1-42 but higher levels of tau, phosphorylated-tau and soluble TREM2. Together, these results suggest that regionally selective white matter degeneration occurs years before the estimated symptom onset. Such white matter alterations are associated with primary Alzheimer's disease pathology and microglia activity in the brain.
Collapse
Affiliation(s)
- Miguel Ángel Araque Caballero
- Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany
| | - Marc Suárez-Calvet
- German Center for Neurodegenerative Diseases (DZNE, Munich), Munich, Germany.,Biomedical Center, Biochemistry, Ludwig-Maximilians-Universität München, Munich, Germany
| | - Marco Duering
- Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany
| | - Nicolai Franzmeier
- Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany
| | - Tammie Benzinger
- Department of Radiology, Washington University in St Louis, St Louis, MO, USA.,Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA
| | - Anne M Fagan
- Department of Radiology, Washington University in St Louis, St Louis, MO, USA.,Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA.,Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO, USA
| | - Randall J Bateman
- Department of Radiology, Washington University in St Louis, St Louis, MO, USA.,Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA.,Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO, USA
| | | | - Johannes Levin
- German Center for Neurodegenerative Diseases (DZNE, Munich), Munich, Germany.,Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany
| | - Martin Dichgans
- Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany.,German Center for Neurodegenerative Diseases (DZNE, Munich), Munich, Germany.,Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
| | - Mathias Jucker
- Hertie Institute for Clinical Brain Research, Tübingen, Germany and German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany
| | - Celeste Karch
- Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA.,Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO, USA.,Department of Psychiatry, Washington University in St Louis, St Louis, MO, USA
| | - Colin L Masters
- The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia
| | - John C Morris
- Department of Radiology, Washington University in St Louis, St Louis, MO, USA.,Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA
| | - Michael Weiner
- University of California at San Francisco, San Francisco, CA94143, USA
| | - Martin Rossor
- Dementia Research Centre, University College London, Queen Square, London, UK
| | - Nick C Fox
- Dementia Research Centre, University College London, Queen Square, London, UK
| | - Jae-Hong Lee
- Department of Neurology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
| | - Stephen Salloway
- Department of Neurology, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA
| | - Adrian Danek
- German Center for Neurodegenerative Diseases (DZNE, Munich), Munich, Germany.,Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany
| | - Alison Goate
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.,Ronald M. Loeb Center for Alzheimer's Disease, Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Igor Yakushev
- Department of Nuclear Medicine, Technical University of Munich, Munich, Germany
| | - Jason Hassenstab
- Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA
| | - Peter R Schofield
- Neuroscience Research Australia, Barker Street Randwick, Sydney, Australia.,School of Medical Sciences, University of New South Wales, Sydney, Australia
| | - Christian Haass
- German Center for Neurodegenerative Diseases (DZNE, Munich), Munich, Germany.,Biomedical Center, Biochemistry, Ludwig-Maximilians-Universität München, Munich, Germany.,Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
| | - Michael Ewers
- Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany
| |
Collapse
|
32
|
Talboom JS, Håberg A, De Both MD, Naymik MA, Schrauwen I, Lewis CR, Bertinelli SF, Hammersland C, Fritz MA, Myers AJ, Hay M, Barnes CA, Glisky E, Ryan L, Huentelman MJ. Family history of Alzheimer's disease alters cognition and is modified by medical and genetic factors. eLife 2019; 8:46179. [PMID: 31210642 PMCID: PMC6615857 DOI: 10.7554/elife.46179] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2019] [Accepted: 06/13/2019] [Indexed: 01/02/2023] Open
Abstract
In humans, a first-degree family history of dementia (FH) is a well-documented risk factor for Alzheimer’s disease (AD); however, the influence of FH on cognition across the lifespan is poorly understood. To address this issue, we developed an internet-based paired-associates learning (PAL) task and tested 59,571 participants between the ages of 18–85. FH was associated with lower PAL performance in both sexes under 65 years old. Modifiers of this effect of FH on PAL performance included age, sex, education, and diabetes. The Apolipoprotein E ε4 allele was also associated with lower PAL scores in FH positive individuals. Here we show, FH is associated with reduced PAL performance four decades before the typical onset of AD; additionally, several heritable and non-heritable modifiers of this effect were identified.
Collapse
Affiliation(s)
- Joshua S Talboom
- The Translational Genomics Research Institute, Phoenix, United States.,Arizona Alzheimer's Consortium, Phoenix, United States
| | - Asta Håberg
- Norwegian University of Science and Technology, Trondheim, Norway
| | - Matthew D De Both
- The Translational Genomics Research Institute, Phoenix, United States.,Arizona Alzheimer's Consortium, Phoenix, United States
| | - Marcus A Naymik
- The Translational Genomics Research Institute, Phoenix, United States.,Arizona Alzheimer's Consortium, Phoenix, United States
| | - Isabelle Schrauwen
- The Translational Genomics Research Institute, Phoenix, United States.,Arizona Alzheimer's Consortium, Phoenix, United States
| | - Candace R Lewis
- The Translational Genomics Research Institute, Phoenix, United States.,Arizona Alzheimer's Consortium, Phoenix, United States
| | | | | | - Mason A Fritz
- The Translational Genomics Research Institute, Phoenix, United States
| | | | - Meredith Hay
- Arizona Alzheimer's Consortium, Phoenix, United States.,University of Arizona, Tucson, United States
| | - Carol A Barnes
- Arizona Alzheimer's Consortium, Phoenix, United States.,University of Arizona, Tucson, United States
| | - Elizabeth Glisky
- Arizona Alzheimer's Consortium, Phoenix, United States.,University of Arizona, Tucson, United States
| | - Lee Ryan
- Arizona Alzheimer's Consortium, Phoenix, United States.,University of Arizona, Tucson, United States
| | - Matthew J Huentelman
- The Translational Genomics Research Institute, Phoenix, United States.,Arizona Alzheimer's Consortium, Phoenix, United States
| |
Collapse
|
33
|
Martínez JF, Trujillo C, Arévalo A, Ibáñez A, Cardona JF. Assessment of Conjunctive Binding in Aging: A Promising Approach for Alzheimer’s Disease Detection. J Alzheimers Dis 2019; 69:71-81. [DOI: 10.3233/jad-181154] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
| | | | - Analía Arévalo
- Department of Neurology, University of São Paulo Medical School, São Paulo, Brazil
| | - Agustín Ibáñez
- Institute of Cognitive and Translational Neuroscience (INCYT), INECO Foundation, Favaloro University, Buenos Aires, Argentina
- National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina
- Center for Social and Cognitive Neuroscience (CSCN), School of Psychology, Universidad Adolfo Ibanez, Santiago, Chile
- Centre of Excellence in Cognition and its Disorders, Australian Research Council (ACR), Sydney, Australia
| | - Juan F. Cardona
- Instituto de Psicología, Universidad del Valle, Cali, Colombia
| |
Collapse
|
34
|
Fallon SJ, Dolfen N, Parolo F, Zokaei N, Husain M. Task-irrelevant financial losses inhibit the removal of information from working memory. Sci Rep 2019; 9:1673. [PMID: 30737421 PMCID: PMC6368543 DOI: 10.1038/s41598-018-36826-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2018] [Accepted: 11/23/2018] [Indexed: 11/09/2022] Open
Abstract
The receipt of financial rewards or penalties - though task-irrelevant - may exert an obligatory effect on manipulating items in working memory (WM) by constraining a forthcoming shift in attention or reinforcing attentional shifts that have previously occurred. Here, we adjudicate between these two hypotheses by varying – after encoding- the order in which task-irrelevant financial outcomes and cues indicating which items need to be retained in memory are presented (so called retrocues). We employed a “what-is-where” design that allowed for the fractionation of WM recall into separate components: identification, precision and binding (between location and identity). Principally, valence-dependent effects were observed only for precision and binding, but only when outcomes were presented before, rather than after, the retrocue. Specifically, task-irrelevant financial losses presented before the retrocue caused a systematic breakdown in binding (misbinding), whereby the features of cued and non-cued memoranda became confused, i.e., the features that made up relevant memoranda were displaced by those of non-cued (irrelevant) items. A control experiment, in which outcomes but no cues were presented, failed to produce the same effects, indicating that the inclusion of retrocues were necessary for generating this effect. These results show that the receipt of financial penalties – even when uncoupled to performance – can prevent irrelevant information from being effectively pruned from WM. These results illustrate the importance of reward-related processing to controlling the contents of WM.
Collapse
Affiliation(s)
- Sean James Fallon
- Department of Experimental Psychology, University of Oxford, Oxford, UK.
| | - Nina Dolfen
- Department of Experimental Psychology, University of Oxford, Oxford, UK.,Motor Control & Neuroplasticity Research Group, KU Leuven, Leuven, Belgium
| | - Francesca Parolo
- Department of Experimental Psychology, University of Oxford, Oxford, UK
| | - Nahid Zokaei
- Department of Experimental Psychology, University of Oxford, Oxford, UK.,Oxford Centre for Human Brain Activity, Wellcome Centre for Integrative Neuroimaging, Department of Psychiatry, University of Oxford, Oxford, UK
| | - Masud Husain
- Department of Experimental Psychology, University of Oxford, Oxford, UK.,Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK
| |
Collapse
|
35
|
Gu X, Chu T, Liu L, Han X. Genetic influences on white matter and metabolism abnormal change in Alzheimer's disease: Meta-analysis for neuroimaging research on presenilin 1 mutation. Clin Neurol Neurosurg 2019; 177:47-53. [PMID: 30599314 DOI: 10.1016/j.clineuro.2018.12.016] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2018] [Revised: 10/18/2018] [Accepted: 12/24/2018] [Indexed: 11/19/2022]
Abstract
Mutations in the presenilin1 (PSEN1) cause familial Alzheimer's disease (FAD), providing a special opportunity to study pre-symptomatic individuals who would be predicted to develop Alzheimer's disease (AD) in the future. However, whether presenilin1 (PSEN1) genotype and neuroimaging markers is a harbinger of AD remains controversial. We aimed to explore the association of PSEN1 genotype with neuroimaging markers of AD: white matter integrity, cerebral amyloid deposition and brain metabolism. We reviewed studies of diffusion tensor imaging (DTI), amyloid deposition and cerebral metabolism in patients with AD and control, in order to address the relative change of white matter microstructural associated with PSEN1 genotype. We performed a systematic meta-analysis and review of 11 cross-sectional studies identified in several database from 2008 to 2018 (n = 165). The pooled standard mean difference (SMD) value was calculated to estimate the association between PSEN1 and white matter change and brain metabolism. PSEN1 mutation carrier status was associated with mean diffusivity (MD) change (pooled SMD: 2.29; 95% CI 1.04 to 3.53; p < 0.001) and increased cerebral amyloid positron emission tomography tracer (pooled SMD: 3.78, 95% CI 1.04 to 6.53, p = 0.007). PSEN1 was not associated with white matter metabolism change (p = 0.069). PSEN1 was associated with mean diffusivity (MD) increase in DTI markers and decreased brain metabolism. Theses associations may suggest the potential role of the PSEN1 gene and imaging marker in Alzheimer's disease.
Collapse
Affiliation(s)
- Xiaochun Gu
- Jiangsu Key Laboratory of Molecular and Functional Imaging, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, 87 Dingjiaqiao Road, Nanjing 210009, China; Key Laboratory of Developmental Genes and Human Diseases, Department of Histology Embryology, Medical School, Southeast University, 87 Dingjiaqiao Road, Nanjing 210009, China.
| | - Tao Chu
- Nanjing Normal University Affiliated Middle School Xincheng Junior High School, 123 Huangshan Road, Nanjing 210009, China
| | - Li Liu
- Key Laboratory of Developmental Genes and Human Diseases, Department of Histology Embryology, Medical School, Southeast University, 87 Dingjiaqiao Road, Nanjing 210009, China
| | - Xiao Han
- Key Laboratory of Developmental Genes and Human Diseases, Department of Histology Embryology, Medical School, Southeast University, 87 Dingjiaqiao Road, Nanjing 210009, China
| |
Collapse
|
36
|
Ibi D, Tsuchihashi A, Nomura T, Hiramatsu M. Involvement of GAT2/BGT-1 in the preventive effects of betaine on cognitive impairment and brain oxidative stress in amyloid β peptide-injected mice. Eur J Pharmacol 2019; 842:57-63. [DOI: 10.1016/j.ejphar.2018.10.037] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2018] [Revised: 10/13/2018] [Accepted: 10/25/2018] [Indexed: 12/17/2022]
|
37
|
Schneegans S, Bays PM. New perspectives on binding in visual working memory. Br J Psychol 2018; 110:207-244. [DOI: 10.1111/bjop.12345] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2018] [Revised: 07/06/2018] [Indexed: 12/01/2022]
Affiliation(s)
| | - Paul M. Bays
- Department of Psychology; University of Cambridge; UK
| |
Collapse
|
38
|
Fernández G, Orozco D, Agamennoni O, Schumacher M, Sañudo S, Biondi J, Parra MA. Visual Processing during Short-Term Memory Binding in Mild Alzheimer’s Disease. J Alzheimers Dis 2018; 63:185-194. [DOI: 10.3233/jad-170728] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- Gerardo Fernández
- Universidad Nacional del Sur (UNS), Bahía Blanca, Argentina, Instituto de Investigaciones en Ingeniería Eléctrica (IIIE) (UNS-CONICET), Bahía Blanca, Buenos Aires, Argentina
| | - David Orozco
- Clínica Privada Bahiense, Bahía Blanca, Buenos Aires, Argentina
| | - Osvaldo Agamennoni
- Universidad Nacional del Sur (UNS), Bahía Blanca, Argentina, Instituto de Investigaciones en Ingeniería Eléctrica (IIIE) (UNS-CONICET), Bahía Blanca, Buenos Aires, Argentina
| | - Marcela Schumacher
- Universidad Nacional del Sur (UNS), Bahía Blanca, Argentina, Instituto de Investigaciones en Ingeniería Eléctrica (IIIE) (UNS-CONICET), Bahía Blanca, Buenos Aires, Argentina
| | - Silvana Sañudo
- Universidad Nacional del Sur (UNS), Bahía Blanca, Argentina, Instituto de Investigaciones en Ingeniería Eléctrica (IIIE) (UNS-CONICET), Bahía Blanca, Buenos Aires, Argentina
| | - Juan Biondi
- Universidad Nacional del Sur (UNS), Bahía Blanca, Argentina, Instituto de Investigaciones en Ingeniería Eléctrica (IIIE) (UNS-CONICET), Bahía Blanca, Buenos Aires, Argentina
| | - Mario A. Parra
- Department of Psychology, School of Social Sciences, Heriot-Watt University, Edinburgh, UK
- Universidad Autónoma del Caribe, Facultad de Psicología, Barranquilla, Colombia
| |
Collapse
|
39
|
Ibáñez A, Sedeño L, García AM, Deacon RMJ, Cogram P. Editorial: Human and Animal Models for Translational Research on Neurodegeneration: Challenges and Opportunities From South America. Front Aging Neurosci 2018; 10:95. [PMID: 29681845 PMCID: PMC5897422 DOI: 10.3389/fnagi.2018.00095] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2017] [Accepted: 03/20/2018] [Indexed: 11/13/2022] Open
Affiliation(s)
- Agustín Ibáñez
- Laboratory of Experimental Psychology and Neuroscience (LPEN), Institute of Cognitive and Translational Neuroscience (INCYT), INECO Foundation, Favaloro University, Buenos Aires, Argentina.,National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.,Universidad Autónoma del Caribe, Barranquilla, Colombia.,Center for Social and Cognitive Neuroscience (CSCN), School of Psychology, Universidad Adolfo Ibáñez, Santiago, Chile.,Centre of Excellence in Cognition and its Disorders, Australian Research Council (ACR), Sydney, NSW, Australia
| | - Lucas Sedeño
- Laboratory of Experimental Psychology and Neuroscience (LPEN), Institute of Cognitive and Translational Neuroscience (INCYT), INECO Foundation, Favaloro University, Buenos Aires, Argentina.,National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina
| | - Adolfo M García
- Laboratory of Experimental Psychology and Neuroscience (LPEN), Institute of Cognitive and Translational Neuroscience (INCYT), INECO Foundation, Favaloro University, Buenos Aires, Argentina.,National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.,Faculty of Education, National University of Cuyo (UNCuyo), Mendoza, Argentina
| | - Robert M J Deacon
- Laboratory of Experimental Psychology and Neuroscience (LPEN), Institute of Cognitive and Translational Neuroscience (INCYT), INECO Foundation, Favaloro University, Buenos Aires, Argentina.,Faculty of Science, Institute of Ecology and Biodiversity, University of Chile, Santiago, Chile
| | - Patricia Cogram
- Laboratory of Experimental Psychology and Neuroscience (LPEN), Institute of Cognitive and Translational Neuroscience (INCYT), INECO Foundation, Favaloro University, Buenos Aires, Argentina.,Faculty of Science, Institute of Ecology and Biodiversity, University of Chile, Santiago, Chile
| |
Collapse
|
40
|
Abstract
UNLABELLED ABSTRACTBackground:Cognitive markers of early Alzheimer's disease (AD) should be sensitive and specific to memory impairments that are not associated with healthy cognitive aging. In the present study, we investigated the effect of healthy cognitive aging on two proposed cognitive markers of AD: the Free and Cued Selective Reminding Task with Immediate Recall (FCSRT-IR) and a temporary visual memory binding (TMB) task. METHOD Free recall and the cost of holding bound information in visual memory were compared between 24 younger and 24 older participants in a mixed, fully counterbalanced experiment. RESULTS A significant effect of age was observed on free recall in the FCSRT-IR only and not on the cost of binding in the TMB task. CONCLUSIONS Of these two cognitive markers, the TMB task is more likely to be specific to memory impairments that are independent of age.
Collapse
|
41
|
Parra MA, Baez S, Allegri R, Nitrini R, Lopera F, Slachevsky A, Custodio N, Lira D, Piguet O, Kumfor F, Huepe D, Cogram P, Bak T, Manes F, Ibanez A. Dementia in Latin America: Assessing the present and envisioning the future. Neurology 2018; 90:222-231. [PMID: 29305437 PMCID: PMC5791795 DOI: 10.1212/wnl.0000000000004897] [Citation(s) in RCA: 108] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2017] [Accepted: 10/02/2017] [Indexed: 01/26/2023] Open
Abstract
The demographic structure of Latin American countries (LAC) is fast approaching that of developing countries, and the predicted prevalence of dementia in the former already exceeds the latter. Dementia has been declared a global challenge, yet regions around the world show differences in both the nature and magnitude of such a challenge. This article provides evidence and insights on barriers which, if overcome, would enable the harmonization of strategies to tackle the dementia challenge in LAC. First, we analyze the lack of available epidemiologic data, the need for standardizing clinical practice and improving physician training, and the existing barriers regarding resources, culture, and stigmas. We discuss how these are preventing timely care and research. Regarding specific health actions, most LAC have minimal mental health facilities and do not have specific mental health policies or budgets specific to dementia. In addition, local regulations may need to consider the regional context when developing treatment and prevention strategies. The support needed nationally and internationally to enable a smooth and timely transition of LAC to a position that integrates global strategies is highlighted. We focus on shared issues of poverty, cultural barriers, and socioeconomic vulnerability. We identify avenues for collaboration aimed to study unique populations, improve valid assessment methods, and generate opportunities for translational research, thus establishing a regional network. The issues identified here point to future specific actions aimed at tackling the dementia challenge in LAC.
Collapse
Affiliation(s)
- Mario A Parra
- From the School of Life Sciences (M.A.P.), Psychology, University Heriot-Watt; Human Cognitive Neuroscience (M.A.P.), Psychology, Edinburgh University; Alzheimer's Scotland Dementia Research Centre and Scottish Dementia Clinical Research Network (M.A.P.), Edinburgh; Centre for Cognitive Ageing and Cognitive Epidemiology (M.A.P., T.B.) and Department of Psychology, School of Philosophy, Psychology and Language Sciences (P.C., T.B.), University of Edinburgh, UK; Universidad Autónoma del Caribe (M.A.P., A.I.), Barranquilla, Colombia; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) (S.B., F.M., A.I.); Institute of Translational and Cognitive Neuroscience (INCYT) (S.B., F.M., A.I.), INECO Foundation, Favaloro University, Buenos Aires, Argentina; Departamento de Psicología (S.B.) Universidad de los Andes, Bogotá, Colombia; Department of Cognitive Neurology and Neuropsychology (R.A.), Instituto de Investigaciones Neurológicas "Raúl Carrea" (FLENI) (R.A.), Buenos Aires, Argentina; Universidad de la Costa (CUC) (R.A.), Barranquilla, Colombia; Department of Neurology (R.N.), University of São Paulo Medical School, Brazil; Group of Neuroscience (F.L.), University of Antioquia, Medellín, Colombia; Geroscience Center for Brain Health and Metabolism (A.S.); Physiopathology Department, ICBM, and East Neuroscience Department, Faculty of Medicine (A.S.), and Center for Advanced Research in Education (CIAE) (A.S.), University of Chile; Cognitive Neurology and Dementia, Neurology Department (A.S.), Hospital del Salvador; Neurology Department, Clínica Alemana (A.S.), Santiago, Chile; Research Unit, Peruvian Institute of Neurosciences (N.C., D.L.) and Unit Cognitive Impairment and Dementia Prevention (N.C., D.L.), Lima, Peru; Brain and Mind Centre & School of Psychology (O.P., F.K.), Faculty of Science, University of Sydney; ARC Centre of Excellence in Cognition and its Disorders (O.P., F.K., F.M., A.I.), Sydney, Australia; Fraunhofer Chile (O.P., P.C.), Santiago; and Center for Social and Cognitive Neuroscience (CSCN), School of Psychology (D.H., A.I.), Universidad Adolfo Ibáñez, Santiago, Chile
| | - Sandra Baez
- From the School of Life Sciences (M.A.P.), Psychology, University Heriot-Watt; Human Cognitive Neuroscience (M.A.P.), Psychology, Edinburgh University; Alzheimer's Scotland Dementia Research Centre and Scottish Dementia Clinical Research Network (M.A.P.), Edinburgh; Centre for Cognitive Ageing and Cognitive Epidemiology (M.A.P., T.B.) and Department of Psychology, School of Philosophy, Psychology and Language Sciences (P.C., T.B.), University of Edinburgh, UK; Universidad Autónoma del Caribe (M.A.P., A.I.), Barranquilla, Colombia; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) (S.B., F.M., A.I.); Institute of Translational and Cognitive Neuroscience (INCYT) (S.B., F.M., A.I.), INECO Foundation, Favaloro University, Buenos Aires, Argentina; Departamento de Psicología (S.B.) Universidad de los Andes, Bogotá, Colombia; Department of Cognitive Neurology and Neuropsychology (R.A.), Instituto de Investigaciones Neurológicas "Raúl Carrea" (FLENI) (R.A.), Buenos Aires, Argentina; Universidad de la Costa (CUC) (R.A.), Barranquilla, Colombia; Department of Neurology (R.N.), University of São Paulo Medical School, Brazil; Group of Neuroscience (F.L.), University of Antioquia, Medellín, Colombia; Geroscience Center for Brain Health and Metabolism (A.S.); Physiopathology Department, ICBM, and East Neuroscience Department, Faculty of Medicine (A.S.), and Center for Advanced Research in Education (CIAE) (A.S.), University of Chile; Cognitive Neurology and Dementia, Neurology Department (A.S.), Hospital del Salvador; Neurology Department, Clínica Alemana (A.S.), Santiago, Chile; Research Unit, Peruvian Institute of Neurosciences (N.C., D.L.) and Unit Cognitive Impairment and Dementia Prevention (N.C., D.L.), Lima, Peru; Brain and Mind Centre & School of Psychology (O.P., F.K.), Faculty of Science, University of Sydney; ARC Centre of Excellence in Cognition and its Disorders (O.P., F.K., F.M., A.I.), Sydney, Australia; Fraunhofer Chile (O.P., P.C.), Santiago; and Center for Social and Cognitive Neuroscience (CSCN), School of Psychology (D.H., A.I.), Universidad Adolfo Ibáñez, Santiago, Chile
| | - Ricardo Allegri
- From the School of Life Sciences (M.A.P.), Psychology, University Heriot-Watt; Human Cognitive Neuroscience (M.A.P.), Psychology, Edinburgh University; Alzheimer's Scotland Dementia Research Centre and Scottish Dementia Clinical Research Network (M.A.P.), Edinburgh; Centre for Cognitive Ageing and Cognitive Epidemiology (M.A.P., T.B.) and Department of Psychology, School of Philosophy, Psychology and Language Sciences (P.C., T.B.), University of Edinburgh, UK; Universidad Autónoma del Caribe (M.A.P., A.I.), Barranquilla, Colombia; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) (S.B., F.M., A.I.); Institute of Translational and Cognitive Neuroscience (INCYT) (S.B., F.M., A.I.), INECO Foundation, Favaloro University, Buenos Aires, Argentina; Departamento de Psicología (S.B.) Universidad de los Andes, Bogotá, Colombia; Department of Cognitive Neurology and Neuropsychology (R.A.), Instituto de Investigaciones Neurológicas "Raúl Carrea" (FLENI) (R.A.), Buenos Aires, Argentina; Universidad de la Costa (CUC) (R.A.), Barranquilla, Colombia; Department of Neurology (R.N.), University of São Paulo Medical School, Brazil; Group of Neuroscience (F.L.), University of Antioquia, Medellín, Colombia; Geroscience Center for Brain Health and Metabolism (A.S.); Physiopathology Department, ICBM, and East Neuroscience Department, Faculty of Medicine (A.S.), and Center for Advanced Research in Education (CIAE) (A.S.), University of Chile; Cognitive Neurology and Dementia, Neurology Department (A.S.), Hospital del Salvador; Neurology Department, Clínica Alemana (A.S.), Santiago, Chile; Research Unit, Peruvian Institute of Neurosciences (N.C., D.L.) and Unit Cognitive Impairment and Dementia Prevention (N.C., D.L.), Lima, Peru; Brain and Mind Centre & School of Psychology (O.P., F.K.), Faculty of Science, University of Sydney; ARC Centre of Excellence in Cognition and its Disorders (O.P., F.K., F.M., A.I.), Sydney, Australia; Fraunhofer Chile (O.P., P.C.), Santiago; and Center for Social and Cognitive Neuroscience (CSCN), School of Psychology (D.H., A.I.), Universidad Adolfo Ibáñez, Santiago, Chile
| | - Ricardo Nitrini
- From the School of Life Sciences (M.A.P.), Psychology, University Heriot-Watt; Human Cognitive Neuroscience (M.A.P.), Psychology, Edinburgh University; Alzheimer's Scotland Dementia Research Centre and Scottish Dementia Clinical Research Network (M.A.P.), Edinburgh; Centre for Cognitive Ageing and Cognitive Epidemiology (M.A.P., T.B.) and Department of Psychology, School of Philosophy, Psychology and Language Sciences (P.C., T.B.), University of Edinburgh, UK; Universidad Autónoma del Caribe (M.A.P., A.I.), Barranquilla, Colombia; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) (S.B., F.M., A.I.); Institute of Translational and Cognitive Neuroscience (INCYT) (S.B., F.M., A.I.), INECO Foundation, Favaloro University, Buenos Aires, Argentina; Departamento de Psicología (S.B.) Universidad de los Andes, Bogotá, Colombia; Department of Cognitive Neurology and Neuropsychology (R.A.), Instituto de Investigaciones Neurológicas "Raúl Carrea" (FLENI) (R.A.), Buenos Aires, Argentina; Universidad de la Costa (CUC) (R.A.), Barranquilla, Colombia; Department of Neurology (R.N.), University of São Paulo Medical School, Brazil; Group of Neuroscience (F.L.), University of Antioquia, Medellín, Colombia; Geroscience Center for Brain Health and Metabolism (A.S.); Physiopathology Department, ICBM, and East Neuroscience Department, Faculty of Medicine (A.S.), and Center for Advanced Research in Education (CIAE) (A.S.), University of Chile; Cognitive Neurology and Dementia, Neurology Department (A.S.), Hospital del Salvador; Neurology Department, Clínica Alemana (A.S.), Santiago, Chile; Research Unit, Peruvian Institute of Neurosciences (N.C., D.L.) and Unit Cognitive Impairment and Dementia Prevention (N.C., D.L.), Lima, Peru; Brain and Mind Centre & School of Psychology (O.P., F.K.), Faculty of Science, University of Sydney; ARC Centre of Excellence in Cognition and its Disorders (O.P., F.K., F.M., A.I.), Sydney, Australia; Fraunhofer Chile (O.P., P.C.), Santiago; and Center for Social and Cognitive Neuroscience (CSCN), School of Psychology (D.H., A.I.), Universidad Adolfo Ibáñez, Santiago, Chile
| | - Francisco Lopera
- From the School of Life Sciences (M.A.P.), Psychology, University Heriot-Watt; Human Cognitive Neuroscience (M.A.P.), Psychology, Edinburgh University; Alzheimer's Scotland Dementia Research Centre and Scottish Dementia Clinical Research Network (M.A.P.), Edinburgh; Centre for Cognitive Ageing and Cognitive Epidemiology (M.A.P., T.B.) and Department of Psychology, School of Philosophy, Psychology and Language Sciences (P.C., T.B.), University of Edinburgh, UK; Universidad Autónoma del Caribe (M.A.P., A.I.), Barranquilla, Colombia; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) (S.B., F.M., A.I.); Institute of Translational and Cognitive Neuroscience (INCYT) (S.B., F.M., A.I.), INECO Foundation, Favaloro University, Buenos Aires, Argentina; Departamento de Psicología (S.B.) Universidad de los Andes, Bogotá, Colombia; Department of Cognitive Neurology and Neuropsychology (R.A.), Instituto de Investigaciones Neurológicas "Raúl Carrea" (FLENI) (R.A.), Buenos Aires, Argentina; Universidad de la Costa (CUC) (R.A.), Barranquilla, Colombia; Department of Neurology (R.N.), University of São Paulo Medical School, Brazil; Group of Neuroscience (F.L.), University of Antioquia, Medellín, Colombia; Geroscience Center for Brain Health and Metabolism (A.S.); Physiopathology Department, ICBM, and East Neuroscience Department, Faculty of Medicine (A.S.), and Center for Advanced Research in Education (CIAE) (A.S.), University of Chile; Cognitive Neurology and Dementia, Neurology Department (A.S.), Hospital del Salvador; Neurology Department, Clínica Alemana (A.S.), Santiago, Chile; Research Unit, Peruvian Institute of Neurosciences (N.C., D.L.) and Unit Cognitive Impairment and Dementia Prevention (N.C., D.L.), Lima, Peru; Brain and Mind Centre & School of Psychology (O.P., F.K.), Faculty of Science, University of Sydney; ARC Centre of Excellence in Cognition and its Disorders (O.P., F.K., F.M., A.I.), Sydney, Australia; Fraunhofer Chile (O.P., P.C.), Santiago; and Center for Social and Cognitive Neuroscience (CSCN), School of Psychology (D.H., A.I.), Universidad Adolfo Ibáñez, Santiago, Chile
| | - Andrea Slachevsky
- From the School of Life Sciences (M.A.P.), Psychology, University Heriot-Watt; Human Cognitive Neuroscience (M.A.P.), Psychology, Edinburgh University; Alzheimer's Scotland Dementia Research Centre and Scottish Dementia Clinical Research Network (M.A.P.), Edinburgh; Centre for Cognitive Ageing and Cognitive Epidemiology (M.A.P., T.B.) and Department of Psychology, School of Philosophy, Psychology and Language Sciences (P.C., T.B.), University of Edinburgh, UK; Universidad Autónoma del Caribe (M.A.P., A.I.), Barranquilla, Colombia; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) (S.B., F.M., A.I.); Institute of Translational and Cognitive Neuroscience (INCYT) (S.B., F.M., A.I.), INECO Foundation, Favaloro University, Buenos Aires, Argentina; Departamento de Psicología (S.B.) Universidad de los Andes, Bogotá, Colombia; Department of Cognitive Neurology and Neuropsychology (R.A.), Instituto de Investigaciones Neurológicas "Raúl Carrea" (FLENI) (R.A.), Buenos Aires, Argentina; Universidad de la Costa (CUC) (R.A.), Barranquilla, Colombia; Department of Neurology (R.N.), University of São Paulo Medical School, Brazil; Group of Neuroscience (F.L.), University of Antioquia, Medellín, Colombia; Geroscience Center for Brain Health and Metabolism (A.S.); Physiopathology Department, ICBM, and East Neuroscience Department, Faculty of Medicine (A.S.), and Center for Advanced Research in Education (CIAE) (A.S.), University of Chile; Cognitive Neurology and Dementia, Neurology Department (A.S.), Hospital del Salvador; Neurology Department, Clínica Alemana (A.S.), Santiago, Chile; Research Unit, Peruvian Institute of Neurosciences (N.C., D.L.) and Unit Cognitive Impairment and Dementia Prevention (N.C., D.L.), Lima, Peru; Brain and Mind Centre & School of Psychology (O.P., F.K.), Faculty of Science, University of Sydney; ARC Centre of Excellence in Cognition and its Disorders (O.P., F.K., F.M., A.I.), Sydney, Australia; Fraunhofer Chile (O.P., P.C.), Santiago; and Center for Social and Cognitive Neuroscience (CSCN), School of Psychology (D.H., A.I.), Universidad Adolfo Ibáñez, Santiago, Chile
| | - Nilton Custodio
- From the School of Life Sciences (M.A.P.), Psychology, University Heriot-Watt; Human Cognitive Neuroscience (M.A.P.), Psychology, Edinburgh University; Alzheimer's Scotland Dementia Research Centre and Scottish Dementia Clinical Research Network (M.A.P.), Edinburgh; Centre for Cognitive Ageing and Cognitive Epidemiology (M.A.P., T.B.) and Department of Psychology, School of Philosophy, Psychology and Language Sciences (P.C., T.B.), University of Edinburgh, UK; Universidad Autónoma del Caribe (M.A.P., A.I.), Barranquilla, Colombia; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) (S.B., F.M., A.I.); Institute of Translational and Cognitive Neuroscience (INCYT) (S.B., F.M., A.I.), INECO Foundation, Favaloro University, Buenos Aires, Argentina; Departamento de Psicología (S.B.) Universidad de los Andes, Bogotá, Colombia; Department of Cognitive Neurology and Neuropsychology (R.A.), Instituto de Investigaciones Neurológicas "Raúl Carrea" (FLENI) (R.A.), Buenos Aires, Argentina; Universidad de la Costa (CUC) (R.A.), Barranquilla, Colombia; Department of Neurology (R.N.), University of São Paulo Medical School, Brazil; Group of Neuroscience (F.L.), University of Antioquia, Medellín, Colombia; Geroscience Center for Brain Health and Metabolism (A.S.); Physiopathology Department, ICBM, and East Neuroscience Department, Faculty of Medicine (A.S.), and Center for Advanced Research in Education (CIAE) (A.S.), University of Chile; Cognitive Neurology and Dementia, Neurology Department (A.S.), Hospital del Salvador; Neurology Department, Clínica Alemana (A.S.), Santiago, Chile; Research Unit, Peruvian Institute of Neurosciences (N.C., D.L.) and Unit Cognitive Impairment and Dementia Prevention (N.C., D.L.), Lima, Peru; Brain and Mind Centre & School of Psychology (O.P., F.K.), Faculty of Science, University of Sydney; ARC Centre of Excellence in Cognition and its Disorders (O.P., F.K., F.M., A.I.), Sydney, Australia; Fraunhofer Chile (O.P., P.C.), Santiago; and Center for Social and Cognitive Neuroscience (CSCN), School of Psychology (D.H., A.I.), Universidad Adolfo Ibáñez, Santiago, Chile
| | - David Lira
- From the School of Life Sciences (M.A.P.), Psychology, University Heriot-Watt; Human Cognitive Neuroscience (M.A.P.), Psychology, Edinburgh University; Alzheimer's Scotland Dementia Research Centre and Scottish Dementia Clinical Research Network (M.A.P.), Edinburgh; Centre for Cognitive Ageing and Cognitive Epidemiology (M.A.P., T.B.) and Department of Psychology, School of Philosophy, Psychology and Language Sciences (P.C., T.B.), University of Edinburgh, UK; Universidad Autónoma del Caribe (M.A.P., A.I.), Barranquilla, Colombia; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) (S.B., F.M., A.I.); Institute of Translational and Cognitive Neuroscience (INCYT) (S.B., F.M., A.I.), INECO Foundation, Favaloro University, Buenos Aires, Argentina; Departamento de Psicología (S.B.) Universidad de los Andes, Bogotá, Colombia; Department of Cognitive Neurology and Neuropsychology (R.A.), Instituto de Investigaciones Neurológicas "Raúl Carrea" (FLENI) (R.A.), Buenos Aires, Argentina; Universidad de la Costa (CUC) (R.A.), Barranquilla, Colombia; Department of Neurology (R.N.), University of São Paulo Medical School, Brazil; Group of Neuroscience (F.L.), University of Antioquia, Medellín, Colombia; Geroscience Center for Brain Health and Metabolism (A.S.); Physiopathology Department, ICBM, and East Neuroscience Department, Faculty of Medicine (A.S.), and Center for Advanced Research in Education (CIAE) (A.S.), University of Chile; Cognitive Neurology and Dementia, Neurology Department (A.S.), Hospital del Salvador; Neurology Department, Clínica Alemana (A.S.), Santiago, Chile; Research Unit, Peruvian Institute of Neurosciences (N.C., D.L.) and Unit Cognitive Impairment and Dementia Prevention (N.C., D.L.), Lima, Peru; Brain and Mind Centre & School of Psychology (O.P., F.K.), Faculty of Science, University of Sydney; ARC Centre of Excellence in Cognition and its Disorders (O.P., F.K., F.M., A.I.), Sydney, Australia; Fraunhofer Chile (O.P., P.C.), Santiago; and Center for Social and Cognitive Neuroscience (CSCN), School of Psychology (D.H., A.I.), Universidad Adolfo Ibáñez, Santiago, Chile
| | - Olivier Piguet
- From the School of Life Sciences (M.A.P.), Psychology, University Heriot-Watt; Human Cognitive Neuroscience (M.A.P.), Psychology, Edinburgh University; Alzheimer's Scotland Dementia Research Centre and Scottish Dementia Clinical Research Network (M.A.P.), Edinburgh; Centre for Cognitive Ageing and Cognitive Epidemiology (M.A.P., T.B.) and Department of Psychology, School of Philosophy, Psychology and Language Sciences (P.C., T.B.), University of Edinburgh, UK; Universidad Autónoma del Caribe (M.A.P., A.I.), Barranquilla, Colombia; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) (S.B., F.M., A.I.); Institute of Translational and Cognitive Neuroscience (INCYT) (S.B., F.M., A.I.), INECO Foundation, Favaloro University, Buenos Aires, Argentina; Departamento de Psicología (S.B.) Universidad de los Andes, Bogotá, Colombia; Department of Cognitive Neurology and Neuropsychology (R.A.), Instituto de Investigaciones Neurológicas "Raúl Carrea" (FLENI) (R.A.), Buenos Aires, Argentina; Universidad de la Costa (CUC) (R.A.), Barranquilla, Colombia; Department of Neurology (R.N.), University of São Paulo Medical School, Brazil; Group of Neuroscience (F.L.), University of Antioquia, Medellín, Colombia; Geroscience Center for Brain Health and Metabolism (A.S.); Physiopathology Department, ICBM, and East Neuroscience Department, Faculty of Medicine (A.S.), and Center for Advanced Research in Education (CIAE) (A.S.), University of Chile; Cognitive Neurology and Dementia, Neurology Department (A.S.), Hospital del Salvador; Neurology Department, Clínica Alemana (A.S.), Santiago, Chile; Research Unit, Peruvian Institute of Neurosciences (N.C., D.L.) and Unit Cognitive Impairment and Dementia Prevention (N.C., D.L.), Lima, Peru; Brain and Mind Centre & School of Psychology (O.P., F.K.), Faculty of Science, University of Sydney; ARC Centre of Excellence in Cognition and its Disorders (O.P., F.K., F.M., A.I.), Sydney, Australia; Fraunhofer Chile (O.P., P.C.), Santiago; and Center for Social and Cognitive Neuroscience (CSCN), School of Psychology (D.H., A.I.), Universidad Adolfo Ibáñez, Santiago, Chile
| | - Fiona Kumfor
- From the School of Life Sciences (M.A.P.), Psychology, University Heriot-Watt; Human Cognitive Neuroscience (M.A.P.), Psychology, Edinburgh University; Alzheimer's Scotland Dementia Research Centre and Scottish Dementia Clinical Research Network (M.A.P.), Edinburgh; Centre for Cognitive Ageing and Cognitive Epidemiology (M.A.P., T.B.) and Department of Psychology, School of Philosophy, Psychology and Language Sciences (P.C., T.B.), University of Edinburgh, UK; Universidad Autónoma del Caribe (M.A.P., A.I.), Barranquilla, Colombia; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) (S.B., F.M., A.I.); Institute of Translational and Cognitive Neuroscience (INCYT) (S.B., F.M., A.I.), INECO Foundation, Favaloro University, Buenos Aires, Argentina; Departamento de Psicología (S.B.) Universidad de los Andes, Bogotá, Colombia; Department of Cognitive Neurology and Neuropsychology (R.A.), Instituto de Investigaciones Neurológicas "Raúl Carrea" (FLENI) (R.A.), Buenos Aires, Argentina; Universidad de la Costa (CUC) (R.A.), Barranquilla, Colombia; Department of Neurology (R.N.), University of São Paulo Medical School, Brazil; Group of Neuroscience (F.L.), University of Antioquia, Medellín, Colombia; Geroscience Center for Brain Health and Metabolism (A.S.); Physiopathology Department, ICBM, and East Neuroscience Department, Faculty of Medicine (A.S.), and Center for Advanced Research in Education (CIAE) (A.S.), University of Chile; Cognitive Neurology and Dementia, Neurology Department (A.S.), Hospital del Salvador; Neurology Department, Clínica Alemana (A.S.), Santiago, Chile; Research Unit, Peruvian Institute of Neurosciences (N.C., D.L.) and Unit Cognitive Impairment and Dementia Prevention (N.C., D.L.), Lima, Peru; Brain and Mind Centre & School of Psychology (O.P., F.K.), Faculty of Science, University of Sydney; ARC Centre of Excellence in Cognition and its Disorders (O.P., F.K., F.M., A.I.), Sydney, Australia; Fraunhofer Chile (O.P., P.C.), Santiago; and Center for Social and Cognitive Neuroscience (CSCN), School of Psychology (D.H., A.I.), Universidad Adolfo Ibáñez, Santiago, Chile
| | - David Huepe
- From the School of Life Sciences (M.A.P.), Psychology, University Heriot-Watt; Human Cognitive Neuroscience (M.A.P.), Psychology, Edinburgh University; Alzheimer's Scotland Dementia Research Centre and Scottish Dementia Clinical Research Network (M.A.P.), Edinburgh; Centre for Cognitive Ageing and Cognitive Epidemiology (M.A.P., T.B.) and Department of Psychology, School of Philosophy, Psychology and Language Sciences (P.C., T.B.), University of Edinburgh, UK; Universidad Autónoma del Caribe (M.A.P., A.I.), Barranquilla, Colombia; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) (S.B., F.M., A.I.); Institute of Translational and Cognitive Neuroscience (INCYT) (S.B., F.M., A.I.), INECO Foundation, Favaloro University, Buenos Aires, Argentina; Departamento de Psicología (S.B.) Universidad de los Andes, Bogotá, Colombia; Department of Cognitive Neurology and Neuropsychology (R.A.), Instituto de Investigaciones Neurológicas "Raúl Carrea" (FLENI) (R.A.), Buenos Aires, Argentina; Universidad de la Costa (CUC) (R.A.), Barranquilla, Colombia; Department of Neurology (R.N.), University of São Paulo Medical School, Brazil; Group of Neuroscience (F.L.), University of Antioquia, Medellín, Colombia; Geroscience Center for Brain Health and Metabolism (A.S.); Physiopathology Department, ICBM, and East Neuroscience Department, Faculty of Medicine (A.S.), and Center for Advanced Research in Education (CIAE) (A.S.), University of Chile; Cognitive Neurology and Dementia, Neurology Department (A.S.), Hospital del Salvador; Neurology Department, Clínica Alemana (A.S.), Santiago, Chile; Research Unit, Peruvian Institute of Neurosciences (N.C., D.L.) and Unit Cognitive Impairment and Dementia Prevention (N.C., D.L.), Lima, Peru; Brain and Mind Centre & School of Psychology (O.P., F.K.), Faculty of Science, University of Sydney; ARC Centre of Excellence in Cognition and its Disorders (O.P., F.K., F.M., A.I.), Sydney, Australia; Fraunhofer Chile (O.P., P.C.), Santiago; and Center for Social and Cognitive Neuroscience (CSCN), School of Psychology (D.H., A.I.), Universidad Adolfo Ibáñez, Santiago, Chile
| | - Patricia Cogram
- From the School of Life Sciences (M.A.P.), Psychology, University Heriot-Watt; Human Cognitive Neuroscience (M.A.P.), Psychology, Edinburgh University; Alzheimer's Scotland Dementia Research Centre and Scottish Dementia Clinical Research Network (M.A.P.), Edinburgh; Centre for Cognitive Ageing and Cognitive Epidemiology (M.A.P., T.B.) and Department of Psychology, School of Philosophy, Psychology and Language Sciences (P.C., T.B.), University of Edinburgh, UK; Universidad Autónoma del Caribe (M.A.P., A.I.), Barranquilla, Colombia; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) (S.B., F.M., A.I.); Institute of Translational and Cognitive Neuroscience (INCYT) (S.B., F.M., A.I.), INECO Foundation, Favaloro University, Buenos Aires, Argentina; Departamento de Psicología (S.B.) Universidad de los Andes, Bogotá, Colombia; Department of Cognitive Neurology and Neuropsychology (R.A.), Instituto de Investigaciones Neurológicas "Raúl Carrea" (FLENI) (R.A.), Buenos Aires, Argentina; Universidad de la Costa (CUC) (R.A.), Barranquilla, Colombia; Department of Neurology (R.N.), University of São Paulo Medical School, Brazil; Group of Neuroscience (F.L.), University of Antioquia, Medellín, Colombia; Geroscience Center for Brain Health and Metabolism (A.S.); Physiopathology Department, ICBM, and East Neuroscience Department, Faculty of Medicine (A.S.), and Center for Advanced Research in Education (CIAE) (A.S.), University of Chile; Cognitive Neurology and Dementia, Neurology Department (A.S.), Hospital del Salvador; Neurology Department, Clínica Alemana (A.S.), Santiago, Chile; Research Unit, Peruvian Institute of Neurosciences (N.C., D.L.) and Unit Cognitive Impairment and Dementia Prevention (N.C., D.L.), Lima, Peru; Brain and Mind Centre & School of Psychology (O.P., F.K.), Faculty of Science, University of Sydney; ARC Centre of Excellence in Cognition and its Disorders (O.P., F.K., F.M., A.I.), Sydney, Australia; Fraunhofer Chile (O.P., P.C.), Santiago; and Center for Social and Cognitive Neuroscience (CSCN), School of Psychology (D.H., A.I.), Universidad Adolfo Ibáñez, Santiago, Chile
| | - Thomas Bak
- From the School of Life Sciences (M.A.P.), Psychology, University Heriot-Watt; Human Cognitive Neuroscience (M.A.P.), Psychology, Edinburgh University; Alzheimer's Scotland Dementia Research Centre and Scottish Dementia Clinical Research Network (M.A.P.), Edinburgh; Centre for Cognitive Ageing and Cognitive Epidemiology (M.A.P., T.B.) and Department of Psychology, School of Philosophy, Psychology and Language Sciences (P.C., T.B.), University of Edinburgh, UK; Universidad Autónoma del Caribe (M.A.P., A.I.), Barranquilla, Colombia; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) (S.B., F.M., A.I.); Institute of Translational and Cognitive Neuroscience (INCYT) (S.B., F.M., A.I.), INECO Foundation, Favaloro University, Buenos Aires, Argentina; Departamento de Psicología (S.B.) Universidad de los Andes, Bogotá, Colombia; Department of Cognitive Neurology and Neuropsychology (R.A.), Instituto de Investigaciones Neurológicas "Raúl Carrea" (FLENI) (R.A.), Buenos Aires, Argentina; Universidad de la Costa (CUC) (R.A.), Barranquilla, Colombia; Department of Neurology (R.N.), University of São Paulo Medical School, Brazil; Group of Neuroscience (F.L.), University of Antioquia, Medellín, Colombia; Geroscience Center for Brain Health and Metabolism (A.S.); Physiopathology Department, ICBM, and East Neuroscience Department, Faculty of Medicine (A.S.), and Center for Advanced Research in Education (CIAE) (A.S.), University of Chile; Cognitive Neurology and Dementia, Neurology Department (A.S.), Hospital del Salvador; Neurology Department, Clínica Alemana (A.S.), Santiago, Chile; Research Unit, Peruvian Institute of Neurosciences (N.C., D.L.) and Unit Cognitive Impairment and Dementia Prevention (N.C., D.L.), Lima, Peru; Brain and Mind Centre & School of Psychology (O.P., F.K.), Faculty of Science, University of Sydney; ARC Centre of Excellence in Cognition and its Disorders (O.P., F.K., F.M., A.I.), Sydney, Australia; Fraunhofer Chile (O.P., P.C.), Santiago; and Center for Social and Cognitive Neuroscience (CSCN), School of Psychology (D.H., A.I.), Universidad Adolfo Ibáñez, Santiago, Chile
| | - Facundo Manes
- From the School of Life Sciences (M.A.P.), Psychology, University Heriot-Watt; Human Cognitive Neuroscience (M.A.P.), Psychology, Edinburgh University; Alzheimer's Scotland Dementia Research Centre and Scottish Dementia Clinical Research Network (M.A.P.), Edinburgh; Centre for Cognitive Ageing and Cognitive Epidemiology (M.A.P., T.B.) and Department of Psychology, School of Philosophy, Psychology and Language Sciences (P.C., T.B.), University of Edinburgh, UK; Universidad Autónoma del Caribe (M.A.P., A.I.), Barranquilla, Colombia; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) (S.B., F.M., A.I.); Institute of Translational and Cognitive Neuroscience (INCYT) (S.B., F.M., A.I.), INECO Foundation, Favaloro University, Buenos Aires, Argentina; Departamento de Psicología (S.B.) Universidad de los Andes, Bogotá, Colombia; Department of Cognitive Neurology and Neuropsychology (R.A.), Instituto de Investigaciones Neurológicas "Raúl Carrea" (FLENI) (R.A.), Buenos Aires, Argentina; Universidad de la Costa (CUC) (R.A.), Barranquilla, Colombia; Department of Neurology (R.N.), University of São Paulo Medical School, Brazil; Group of Neuroscience (F.L.), University of Antioquia, Medellín, Colombia; Geroscience Center for Brain Health and Metabolism (A.S.); Physiopathology Department, ICBM, and East Neuroscience Department, Faculty of Medicine (A.S.), and Center for Advanced Research in Education (CIAE) (A.S.), University of Chile; Cognitive Neurology and Dementia, Neurology Department (A.S.), Hospital del Salvador; Neurology Department, Clínica Alemana (A.S.), Santiago, Chile; Research Unit, Peruvian Institute of Neurosciences (N.C., D.L.) and Unit Cognitive Impairment and Dementia Prevention (N.C., D.L.), Lima, Peru; Brain and Mind Centre & School of Psychology (O.P., F.K.), Faculty of Science, University of Sydney; ARC Centre of Excellence in Cognition and its Disorders (O.P., F.K., F.M., A.I.), Sydney, Australia; Fraunhofer Chile (O.P., P.C.), Santiago; and Center for Social and Cognitive Neuroscience (CSCN), School of Psychology (D.H., A.I.), Universidad Adolfo Ibáñez, Santiago, Chile
| | - Agustin Ibanez
- From the School of Life Sciences (M.A.P.), Psychology, University Heriot-Watt; Human Cognitive Neuroscience (M.A.P.), Psychology, Edinburgh University; Alzheimer's Scotland Dementia Research Centre and Scottish Dementia Clinical Research Network (M.A.P.), Edinburgh; Centre for Cognitive Ageing and Cognitive Epidemiology (M.A.P., T.B.) and Department of Psychology, School of Philosophy, Psychology and Language Sciences (P.C., T.B.), University of Edinburgh, UK; Universidad Autónoma del Caribe (M.A.P., A.I.), Barranquilla, Colombia; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) (S.B., F.M., A.I.); Institute of Translational and Cognitive Neuroscience (INCYT) (S.B., F.M., A.I.), INECO Foundation, Favaloro University, Buenos Aires, Argentina; Departamento de Psicología (S.B.) Universidad de los Andes, Bogotá, Colombia; Department of Cognitive Neurology and Neuropsychology (R.A.), Instituto de Investigaciones Neurológicas "Raúl Carrea" (FLENI) (R.A.), Buenos Aires, Argentina; Universidad de la Costa (CUC) (R.A.), Barranquilla, Colombia; Department of Neurology (R.N.), University of São Paulo Medical School, Brazil; Group of Neuroscience (F.L.), University of Antioquia, Medellín, Colombia; Geroscience Center for Brain Health and Metabolism (A.S.); Physiopathology Department, ICBM, and East Neuroscience Department, Faculty of Medicine (A.S.), and Center for Advanced Research in Education (CIAE) (A.S.), University of Chile; Cognitive Neurology and Dementia, Neurology Department (A.S.), Hospital del Salvador; Neurology Department, Clínica Alemana (A.S.), Santiago, Chile; Research Unit, Peruvian Institute of Neurosciences (N.C., D.L.) and Unit Cognitive Impairment and Dementia Prevention (N.C., D.L.), Lima, Peru; Brain and Mind Centre & School of Psychology (O.P., F.K.), Faculty of Science, University of Sydney; ARC Centre of Excellence in Cognition and its Disorders (O.P., F.K., F.M., A.I.), Sydney, Australia; Fraunhofer Chile (O.P., P.C.), Santiago; and Center for Social and Cognitive Neuroscience (CSCN), School of Psychology (D.H., A.I.), Universidad Adolfo Ibáñez, Santiago, Chile.
| |
Collapse
|
42
|
Birba A, Hesse E, Sedeño L, Mikulan EP, García MDC, Ávalos J, Adolfi F, Legaz A, Bekinschtein TA, Zimerman M, Parra M, García AM, Ibáñez A. Enhanced Working Memory Binding by Direct Electrical Stimulation of the Parietal Cortex. Front Aging Neurosci 2017. [PMID: 28642698 PMCID: PMC5462969 DOI: 10.3389/fnagi.2017.00178] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Recent works evince the critical role of visual short-term memory (STM) binding deficits as a clinical and preclinical marker of Alzheimer’s disease (AD). These studies suggest a potential role of posterior brain regions in both the neurocognitive deficits of Alzheimer’s patients and STM binding in general. Thereupon, we surmised that stimulation of the posterior parietal cortex (PPC) might be a successful approach to tackle working memory deficits in this condition, especially at early stages. To date, no causal evidence exists of the role of the parietal cortex in STM binding. A unique approach to assess this issue is afforded by single-subject direct intracranial electrical stimulation of specific brain regions during a relevant cognitive task. Electrical stimulation has been used both for clinical purposes and to causally probe brain mechanisms. Previous evidence of electrical currents spreading through white matter along well defined functional circuits indicates that visual working memory mechanisms are subserved by a specific widely distributed network. Here, we stimulated the parietal cortex of a subject with intracranial electrodes as he performed the visual STM task. We compared the ensuing results to those from a non-stimulated condition and to the performance of a matched control group. In brief, direct stimulation of the parietal cortex induced a selective improvement in STM. These results, together with previous studies, provide very preliminary but promising ground to examine behavioral changes upon parietal stimulation in AD. We discuss our results regarding: (a) the usefulness of the task to target prodromal stages of AD; (b) the role of a posterior network in STM binding and in AD; and (c) the potential opportunity to improve STM binding through brain stimulation.
Collapse
Affiliation(s)
- Agustina Birba
- Laboratory of Experimental Psychology and Neuroscience (LPEN), Institute of Cognitive and Translational Neuroscience (INCyT), INECO Foundation, Favaloro UniversityBuenos Aires, Argentina.,National Scientific and Technical Research Council (CONICET)Buenos Aires, Argentina
| | - Eugenia Hesse
- Laboratory of Experimental Psychology and Neuroscience (LPEN), Institute of Cognitive and Translational Neuroscience (INCyT), INECO Foundation, Favaloro UniversityBuenos Aires, Argentina.,National Scientific and Technical Research Council (CONICET)Buenos Aires, Argentina.,Instituto de Ingeniería Biomédica, Facultad de Ingeniería, Universidad de Buenos AiresBuenos Aires, Argentina
| | - Lucas Sedeño
- Laboratory of Experimental Psychology and Neuroscience (LPEN), Institute of Cognitive and Translational Neuroscience (INCyT), INECO Foundation, Favaloro UniversityBuenos Aires, Argentina.,National Scientific and Technical Research Council (CONICET)Buenos Aires, Argentina
| | - Ezequiel P Mikulan
- Laboratory of Experimental Psychology and Neuroscience (LPEN), Institute of Cognitive and Translational Neuroscience (INCyT), INECO Foundation, Favaloro UniversityBuenos Aires, Argentina.,National Scientific and Technical Research Council (CONICET)Buenos Aires, Argentina
| | | | - Juan Ávalos
- Hospital Italiano de Buenos AiresBuenos Aires, Argentina
| | - Federico Adolfi
- Laboratory of Experimental Psychology and Neuroscience (LPEN), Institute of Cognitive and Translational Neuroscience (INCyT), INECO Foundation, Favaloro UniversityBuenos Aires, Argentina.,National Scientific and Technical Research Council (CONICET)Buenos Aires, Argentina
| | - Agustina Legaz
- Laboratory of Experimental Psychology and Neuroscience (LPEN), Institute of Cognitive and Translational Neuroscience (INCyT), INECO Foundation, Favaloro UniversityBuenos Aires, Argentina
| | - Tristán A Bekinschtein
- Consciousness and Cognition Laboratory, Department of Psychology, University of CambridgeCambridge, United Kingdom
| | - Máximo Zimerman
- Laboratory of Experimental Psychology and Neuroscience (LPEN), Institute of Cognitive and Translational Neuroscience (INCyT), INECO Foundation, Favaloro UniversityBuenos Aires, Argentina
| | - Mario Parra
- Department of Psychology, School of Social Sciences, Heriot-Watt UniversityEdinburgh, United Kingdom.,Human Cognitive Neuroscience, Centre for Cognitive Ageing and Cognitive Epidemiology, Alzheimer Scotland Dementia Research Centre, Department of Psychology, University of EdinburghEdinburgh, United Kingdom.,Neuroprogressive and Dementia Network, NHS Research ScotlandEdinburgh, United Kingdom.,Facultad de Psicología, Universidad Autónoma del CaribeBarranquilla, Colombia
| | - Adolfo M García
- Laboratory of Experimental Psychology and Neuroscience (LPEN), Institute of Cognitive and Translational Neuroscience (INCyT), INECO Foundation, Favaloro UniversityBuenos Aires, Argentina.,National Scientific and Technical Research Council (CONICET)Buenos Aires, Argentina.,Faculty of Education, National University of Cuyo (UNCuyo)Mendoza, Argentina
| | - Agustín Ibáñez
- Laboratory of Experimental Psychology and Neuroscience (LPEN), Institute of Cognitive and Translational Neuroscience (INCyT), INECO Foundation, Favaloro UniversityBuenos Aires, Argentina.,National Scientific and Technical Research Council (CONICET)Buenos Aires, Argentina.,Facultad de Psicología, Universidad Autónoma del CaribeBarranquilla, Colombia.,Center for Social and Cognitive Neuroscience (CSCN), School of Psychology, Universidad Adolfo IbañezSantiago, Chile.,Centre of Excellence in Cognition and its Disorders, Australian Research Council (ARC)Sydney, NSW, Australia
| |
Collapse
|
43
|
Mak E, Gabel S, Mirette H, Su L, Williams GB, Waldman A, Wells K, Ritchie K, Ritchie C, O’Brien J. Structural neuroimaging in preclinical dementia: From microstructural deficits and grey matter atrophy to macroscale connectomic changes. Ageing Res Rev 2017; 35:250-264. [PMID: 27777039 DOI: 10.1016/j.arr.2016.10.001] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2016] [Revised: 08/26/2016] [Accepted: 10/19/2016] [Indexed: 12/18/2022]
Abstract
The last decade has witnessed a proliferation of neuroimaging studies characterising brain changes associated with Alzheimer's disease (AD), where both widespread atrophy and 'signature' brain regions have been implicated. In parallel, a prolonged latency period has been established in AD, with abnormal cerebral changes beginning many years before symptom onset. This raises the possibility of early therapeutic intervention, even before symptoms, when treatments could have the greatest effect on disease-course modification. Two important prerequisites of this endeavour are (1) accurate characterisation or risk stratification and (2) monitoring of progression using neuroimaging outcomes as a surrogate biomarker in those without symptoms but who will develop AD, here referred to as preclinical AD. Structural neuroimaging modalities have been used to identify brain changes related to risk factors for AD, such as familial genetic mutations, risk genes (for example apolipoprotein epsilon-4 allele), and/or family history. In this review, we summarise structural imaging findings in preclinical AD. Overall, the literature suggests early vulnerability in characteristic regions, such as the medial temporal lobe structures and the precuneus, as well as white matter tracts in the fornix, cingulum and corpus callosum. We conclude that while structural markers are promising, more research and validation studies are needed before future secondary prevention trials can adopt structural imaging biomarkers as either stratification or surrogate biomarkers.
Collapse
|
44
|
Hu YS, Xin J, Hu Y, Zhang L, Wang J. Analyzing the genes related to Alzheimer's disease via a network and pathway-based approach. ALZHEIMERS RESEARCH & THERAPY 2017; 9:29. [PMID: 28446202 PMCID: PMC5406904 DOI: 10.1186/s13195-017-0252-z] [Citation(s) in RCA: 68] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/12/2016] [Accepted: 03/01/2017] [Indexed: 12/29/2022]
Abstract
Background Our understanding of the molecular mechanisms underlying Alzheimer’s disease (AD) remains incomplete. Previous studies have revealed that genetic factors provide a significant contribution to the pathogenesis and development of AD. In the past years, numerous genes implicated in this disease have been identified via genetic association studies on candidate genes or at the genome-wide level. However, in many cases, the roles of these genes and their interactions in AD are still unclear. A comprehensive and systematic analysis focusing on the biological function and interactions of these genes in the context of AD will therefore provide valuable insights to understand the molecular features of the disease. Method In this study, we collected genes potentially associated with AD by screening publications on genetic association studies deposited in PubMed. The major biological themes linked with these genes were then revealed by function and biochemical pathway enrichment analysis, and the relation between the pathways was explored by pathway crosstalk analysis. Furthermore, the network features of these AD-related genes were analyzed in the context of human interactome and an AD-specific network was inferred using the Steiner minimal tree algorithm. Results We compiled 430 human genes reported to be associated with AD from 823 publications. Biological theme analysis indicated that the biological processes and biochemical pathways related to neurodevelopment, metabolism, cell growth and/or survival, and immunology were enriched in these genes. Pathway crosstalk analysis then revealed that the significantly enriched pathways could be grouped into three interlinked modules—neuronal and metabolic module, cell growth/survival and neuroendocrine pathway module, and immune response-related module—indicating an AD-specific immune-endocrine-neuronal regulatory network. Furthermore, an AD-specific protein network was inferred and novel genes potentially associated with AD were identified. Conclusion By means of network and pathway-based methodology, we explored the pathogenetic mechanism underlying AD at a systems biology level. Results from our work could provide valuable clues for understanding the molecular mechanism underlying AD. In addition, the framework proposed in this study could be used to investigate the pathological molecular network and genes relevant to other complex diseases or phenotypes. Electronic supplementary material The online version of this article (doi:10.1186/s13195-017-0252-z) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Yan-Shi Hu
- School of Biomedical Engineering, Tianjin Medical University, Tianjin, 300070, China
| | - Juncai Xin
- School of Biomedical Engineering, Tianjin Medical University, Tianjin, 300070, China
| | - Ying Hu
- School of Biomedical Engineering, Tianjin Medical University, Tianjin, 300070, China
| | - Lei Zhang
- School of Computer Science and Technology, Tianjin University, Tianjin, 300072, China.
| | - Ju Wang
- School of Biomedical Engineering, Tianjin Medical University, Tianjin, 300070, China.
| |
Collapse
|
45
|
Zokaei N, Giehl K, Sillence A, Neville MJ, Karpe F, Nobre AC, Husain M. Sex and APOE: A memory advantage in male APOE ε4 carriers in midlife. Cortex 2017; 88:98-105. [PMID: 28086184 PMCID: PMC5333781 DOI: 10.1016/j.cortex.2016.12.016] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2016] [Revised: 12/05/2016] [Accepted: 12/19/2016] [Indexed: 11/20/2022]
Abstract
Short-term memory in middle-aged individuals with different APOE alleles was examined using a recently developed task which is sensitive to medial temporal lobe (MTL) damage. Individuals (age-range: 40-51 years) with ε3/ε3, ε3/ε4 and ε4/ε4 APOE genotypes (N = 60) performed a delayed estimation task with a sensitive continuous measure of report. The paradigm allowed us to measure memory for items and their locations, as well as maintenance of identity-location feature binding in memory. There was a significant gene-dosage dependent effect of the ε4 allele on performance: memory decay or forgetting was slower in ε4 carriers, as measured by localization error and after controlling for misbinding errors. Furthermore ε4 carriers made less misbinding errors. These findings were specific to male carriers only. Thus, male ε4 carriers are at a behavioral advantage in midlife on a sensitive task of short-term memory. The results would be consistent with an antagonistic pleiotropy hypothesis and hightight the interaction of gender on the influence of APOE in cognition.
Collapse
Affiliation(s)
- Nahid Zokaei
- Oxford Centre for Human Brain Activity, Department of Psychiatry, University of Oxford, Oxford, UK; Department of Experimental Psychology, University of Oxford, Oxford, UK.
| | - Kathrin Giehl
- Department of Nuclear Medicine, University of Cologne, Cologne, Germany
| | - Annie Sillence
- Department of Experimental Psychology, University of Oxford, Oxford, UK
| | - Matt J Neville
- Centre for Diabetes, Endocrinology and Metabolism (OCDEM), University of Oxford, Churchill Hospital, Headington, Oxford, UK; NIHR Oxford Biomedical Research Centre, ORH Trust, Oxford, Churchill Hospital, Oxford, UK
| | - Fredrik Karpe
- Centre for Diabetes, Endocrinology and Metabolism (OCDEM), University of Oxford, Churchill Hospital, Headington, Oxford, UK; NIHR Oxford Biomedical Research Centre, ORH Trust, Oxford, Churchill Hospital, Oxford, UK
| | - Anna C Nobre
- Oxford Centre for Human Brain Activity, Department of Psychiatry, University of Oxford, Oxford, UK; Department of Experimental Psychology, University of Oxford, Oxford, UK
| | - Masud Husain
- Department of Experimental Psychology, University of Oxford, Oxford, UK; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
| |
Collapse
|
46
|
Locating Temporal Functional Dynamics of Visual Short-Term Memory Binding using Graph Modular Dirichlet Energy. Sci Rep 2017; 7:42013. [PMID: 28186173 PMCID: PMC5301217 DOI: 10.1038/srep42013] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2016] [Accepted: 01/05/2017] [Indexed: 11/09/2022] Open
Abstract
Visual short-term memory binding tasks are a promising early marker for Alzheimer's disease (AD). To uncover functional deficits of AD in these tasks it is meaningful to first study unimpaired brain function. Electroencephalogram recordings were obtained from encoding and maintenance periods of tasks performed by healthy young volunteers. We probe the task's transient physiological underpinnings by contrasting shape only (Shape) and shape-colour binding (Bind) conditions, displayed in the left and right sides of the screen, separately. Particularly, we introduce and implement a novel technique named Modular Dirichlet Energy (MDE) which allows robust and flexible analysis of the functional network with unprecedented temporal precision. We find that connectivity in the Bind condition is less integrated with the global network than in the Shape condition in occipital and frontal modules during the encoding period of the right screen condition. Using MDE we are able to discern driving effects in the occipital module between 100-140 ms, coinciding with the P100 visually evoked potential, followed by a driving effect in the frontal module between 140-180 ms, suggesting that the differences found constitute an information processing difference between these modules. This provides temporally precise information over a heterogeneous population in promising tasks for the detection of AD.
Collapse
|
47
|
Sánchez-Valle R, Monté GC, Sala-Llonch R, Bosch B, Fortea J, Lladó A, Antonell A, Balasa M, Bargalló N, Molinuevo JL. White Matter Abnormalities Track Disease Progression in PSEN1 Autosomal Dominant Alzheimer's Disease. J Alzheimers Dis 2016; 51:827-35. [PMID: 26923015 DOI: 10.3233/jad-150899] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
PSEN1 mutations are the most frequent cause of autosomal dominant Alzheimer's disease (ADAD), and show nearly full penetrance. There is presently increasing interest in the study of biomarkers that track disease progression in order to test therapeutic interventions in ADAD. We used white mater (WM) volumetric characteristics and diffusion tensor imaging (DTI) metrics to investigate correlations with the normalized time to expected symptoms onset (relative age ratio) and group differences in a cohort of 36 subjects from PSEN1 ADAD families: 22 mutation carriers, 10 symptomatic (SMC) and 12 asymptomatic (AMC), and 14 non-carriers (NC). Subjects underwent a 3T MRI. WM morphometric data and DTI metrics were analyzed. We found that PSEN1 MC showed significant negative correlation between fractional anisotropy (FA) and the relative age ratio in the genus and body of corpus callosum and corona radiate (p < 0.05 Family-wise error correction (FWE) at cluster level) and positive correlation with mean diffusivity (MD), axial diffusivity (AxD), and radial diffusivity (RD) in the splenium of corpus callosum. SMC presented WM volume loss, reduced FA and increased MD, AxD, and RD in the anterior and posterior corona radiate, corpus callosum (p < 0.05 FWE) compared with NC. No significant differences were observed between AMC and NC in WM volume or DTI measures. These findings suggest that the integrity of the WM deteriorates linearly in PSEN1 ADAD from the early phases of the disease; thus DTI metrics might be useful to monitor the disease progression. However, the lack of significant alterations at the preclinical stages suggests that these indexes might not be good candidates for early markers of the disease.
Collapse
Affiliation(s)
- Raquel Sánchez-Valle
- Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Clínic, Barcelona, Spain.,Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Gemma C Monté
- Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Roser Sala-Llonch
- Research Group for Lifespan Changes in Brain and Cognition (LCBC), Department of Psychology, University of Oslo, Norway
| | - Beatriz Bosch
- Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Clínic, Barcelona, Spain.,Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Juan Fortea
- Memory Unit, Department of Neurology, Hospital de Sant Pau, Barcelona, Spain
| | - Albert Lladó
- Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Clínic, Barcelona, Spain.,Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Anna Antonell
- Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Clínic, Barcelona, Spain.,Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Mircea Balasa
- Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Clínic, Barcelona, Spain.,Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Nuria Bargalló
- Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Department of Radiology, Hospital Clínic, Barcelona, Spain
| | - José Luis Molinuevo
- Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Clínic, Barcelona, Spain.,Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| |
Collapse
|
48
|
Baez S, Ibáñez A. Dementia in Latin America: An Emergent Silent Tsunami. Front Aging Neurosci 2016; 8:253. [PMID: 27840605 PMCID: PMC5083841 DOI: 10.3389/fnagi.2016.00253] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2016] [Accepted: 10/14/2016] [Indexed: 12/16/2022] Open
Affiliation(s)
- Sandra Baez
- Laboratory of Experimental Psychology and Neuroscience, Institute of Cognitive and Translational Neuroscience, INECO Foundation, Favaloro UniversityBuenos Aires, Argentina
- Departamento de Psicología, Universidad de los AndesBogotá, Colombia
| | - Agustín Ibáñez
- Laboratory of Experimental Psychology and Neuroscience, Institute of Cognitive and Translational Neuroscience, INECO Foundation, Favaloro UniversityBuenos Aires, Argentina
- Departamento de Psicología, Universidad Autónoma del CaribeBarranquilla, Colombia
- Center for Social and Cognitive Neuroscience, School of Psychology, Universidad Adolfo IbáñezSantiago de Chile, Chile
- Australian Research Council Centre of Excellence in Cognition and its DisordersSydney, NSW, Australia
| |
Collapse
|
49
|
Palesi F, Castellazzi G, Casiraghi L, Sinforiani E, Vitali P, Gandini Wheeler-Kingshott CAM, D'Angelo E. Exploring Patterns of Alteration in Alzheimer's Disease Brain Networks: A Combined Structural and Functional Connectomics Analysis. Front Neurosci 2016; 10:380. [PMID: 27656119 PMCID: PMC5013043 DOI: 10.3389/fnins.2016.00380] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2016] [Accepted: 08/04/2016] [Indexed: 11/13/2022] Open
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by a severe derangement of cognitive functions, primarily memory, in elderly subjects. As far as the functional impairment is concerned, growing evidence supports the "disconnection syndrome" hypothesis. Recent investigations using fMRI have revealed a generalized alteration of resting state networks (RSNs) in patients affected by AD and mild cognitive impairment (MCI). However, it was unclear whether the changes in functional connectivity were accompanied by corresponding structural network changes. In this work, we have developed a novel structural/functional connectomic approach: resting state fMRI was used to identify the functional cortical network nodes and diffusion MRI to reconstruct the fiber tracts to give a weight to internodal subcortical connections. Then, local and global efficiency were determined for different networks, exploring specific alterations of integration and segregation patterns in AD and MCI patients compared to healthy controls (HC). In the default mode network (DMN), that was the most affected, axonal loss, and reduced axonal integrity appeared to compromise both local and global efficiency along posterior-anterior connections. In the basal ganglia network (BGN), disruption of white matter integrity implied that main alterations occurred in local microstructure. In the anterior insular network (AIN), neuronal loss probably subtended a compromised communication with the insular cortex. Cognitive performance, evaluated by neuropsychological examinations, revealed a dependency on integration and segregation of brain networks. These findings are indicative of the fact that cognitive deficits in AD could be associated not only with cortical alterations (revealed by fMRI) but also with subcortical alterations (revealed by diffusion MRI) that extend beyond the areas primarily damaged by neurodegeneration, toward the support of an emerging concept of AD as a "disconnection syndrome." Since only AD but not MCI patients were characterized by a significant decrease in structural connectivity, integrated structural/functional connectomics could provide a useful tool for assessing disease progression from MCI to AD.
Collapse
Affiliation(s)
- Fulvia Palesi
- Department of Physics, University of PaviaPavia, Italy; Brain Connectivity Center, C. Mondino National Neurological InstitutePavia, Italy
| | - Gloria Castellazzi
- Brain Connectivity Center, C. Mondino National Neurological InstitutePavia, Italy; Department of Electrical, Computer and Biomedical Engineering, University of PaviaPavia, Italy
| | - Letizia Casiraghi
- Brain Connectivity Center, C. Mondino National Neurological InstitutePavia, Italy; Department of Brain and Behavioural Sciences, University of PaviaPavia, Italy
| | - Elena Sinforiani
- Neuroradiology Unit, C. Mondino National Neurological Institute Pavia, Italy
| | - Paolo Vitali
- Neuroradiology Unit, C. Mondino National Neurological InstitutePavia, Italy; Brain MRI 3T Mondino Research Center, C. Mondino National Neurological InstitutePavia, Italy
| | - Claudia A M Gandini Wheeler-Kingshott
- Department of Brain and Behavioural Sciences, University of PaviaPavia, Italy; Brain MRI 3T Mondino Research Center, C. Mondino National Neurological InstitutePavia, Italy; NMR Research Unit, Queen Square MS Centre, Department of Neuroinflammation, UCL Institute of NeurologyLondon, UK
| | - Egidio D'Angelo
- Brain Connectivity Center, C. Mondino National Neurological InstitutePavia, Italy; Department of Brain and Behavioural Sciences, University of PaviaPavia, Italy
| |
Collapse
|
50
|
Pini L, Pievani M, Bocchetta M, Altomare D, Bosco P, Cavedo E, Galluzzi S, Marizzoni M, Frisoni GB. Brain atrophy in Alzheimer's Disease and aging. Ageing Res Rev 2016; 30:25-48. [PMID: 26827786 DOI: 10.1016/j.arr.2016.01.002] [Citation(s) in RCA: 445] [Impact Index Per Article: 55.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2015] [Revised: 01/15/2016] [Accepted: 01/20/2016] [Indexed: 01/22/2023]
Abstract
Thanks to its safety and accessibility, magnetic resonance imaging (MRI) is extensively used in clinical routine and research field, largely contributing to our understanding of the pathophysiology of neurodegenerative disorders such as Alzheimer's disease (AD). This review aims to provide a comprehensive overview of the main findings in AD and normal aging over the past twenty years, focusing on the patterns of gray and white matter changes assessed in vivo using MRI. Major progresses in the field concern the segmentation of the hippocampus with novel manual and automatic segmentation approaches, which might soon enable to assess also hippocampal subfields. Advancements in quantification of hippocampal volumetry might pave the way to its broader use as outcome marker in AD clinical trials. Patterns of cortical atrophy have been shown to accurately track disease progression and seem promising in distinguishing among AD subtypes. Disease progression has also been associated with changes in white matter tracts. Recent studies have investigated two areas often overlooked in AD, such as the striatum and basal forebrain, reporting significant atrophy, although the impact of these changes on cognition is still unclear. Future integration of different MRI modalities may further advance the field by providing more powerful biomarkers of disease onset and progression.
Collapse
Affiliation(s)
- Lorenzo Pini
- Laboratory Alzheimer's Neuroimaging & Epidemiology, IRCCS Fatebenefratelli, Brescia, Italy; Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
| | - Michela Pievani
- Laboratory Alzheimer's Neuroimaging & Epidemiology, IRCCS Fatebenefratelli, Brescia, Italy
| | - Martina Bocchetta
- Laboratory Alzheimer's Neuroimaging & Epidemiology, IRCCS Fatebenefratelli, Brescia, Italy; Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, University College London, London, UK
| | - Daniele Altomare
- Laboratory Alzheimer's Neuroimaging & Epidemiology, IRCCS Fatebenefratelli, Brescia, Italy; Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
| | - Paolo Bosco
- Laboratory Alzheimer's Neuroimaging & Epidemiology, IRCCS Fatebenefratelli, Brescia, Italy
| | - Enrica Cavedo
- Laboratory Alzheimer's Neuroimaging & Epidemiology, IRCCS Fatebenefratelli, Brescia, Italy; Sorbonne Universités, Université Pierre et Marie Curie, Paris 06, Institut de la Mémoire et de la Maladie d'Alzheimer (IM2A) Hôpital de la Pitié-Salpétrière & Institut du Cerveau et de la Moelle épinière (ICM), UMR S 1127, Hôpital de la Pitié-Salpétrière Paris & CATI Multicenter Neuroimaging Platform, France
| | - Samantha Galluzzi
- Laboratory Alzheimer's Neuroimaging & Epidemiology, IRCCS Fatebenefratelli, Brescia, Italy
| | - Moira Marizzoni
- Laboratory Alzheimer's Neuroimaging & Epidemiology, IRCCS Fatebenefratelli, Brescia, Italy
| | - Giovanni B Frisoni
- Laboratory Alzheimer's Neuroimaging & Epidemiology, IRCCS Fatebenefratelli, Brescia, Italy; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland.
| |
Collapse
|